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ABSTRACT 
Introduction: Obesity is a well-known global pandemic that is fundamentally caused by an energy 
imbalance between calories consumed and calories expended. A major consequence to obesity are 
metabolic perturbations that are accompanied by insulin insensitivity and central obesity. Not only, 
but also are these factors associated with metabolic syndrome, they increase the risk of developing 
cardiovascular disease. Recently, obesity has been linked to the development of cancer, particularly 
breast and prostate cancer. While numerous mechanisms have been proposed, by far the biological 
mechanisms that has received much attention include insulin, insulin-like growth factor-1 (IGF-1), 
sex hormones and adipokines. While research on the mechanisms underlying obesity and its 
relationship with cancer are still in the early stages, understanding the processes of carcinogenesis in 
obesity-related cancers may lead to the development of treatments and better preventative strategies. 
Interestingly, the use of doxorubicin (DOX), a potent chemotherapeutic agent, is limited by its 
cumulative, dose- dependent toxicity that can lead to the development and progression of congestive 
heart failure. Considering that these inflammatory diseases have mainly been studied in isolation, 
there are very few, if any studies that have investigated cancer and cardiotoxicity in the context of 
obesity, to better understand the complex relationship that these diseases have with one another and 
how cardiovascular function is adversely affected in this scenario. Therefore, this study hypothesized 
that cancer in an obese environment increases the risk of developing early-stage DOX-induced 
cardiotoxicity.  
Methods: Three-week-old female C57BL6 mice were acclimatized and randomly placed on either a 
high (H) fat diet or standard (S) diet for eight weeks to induce obesity. After eight weeks on the diet, 
these groups were further divided into two more groups were half of the mice in S and in H groups 
were inoculated with EO771 breast cancer cells and the others were not (non-tumour control group). 
Once tumours were palpable, animals were divided into more groups were some received DOX 
treatment. Each animal on treatment received three intraperitoneal injections of 4 mg/kg DOX 
resulting in a cumulative dose of 12 mg/kg. Animals remained on their respective diets for the 
duration of the study and were monitored daily. Four days after the last injection, animals were 
weighted, euthanized and their hearts excised. The blood collected was used to analyse circulating 
cytokines, adipokines and other markers of cardiovascular damage, while heart tissue was preserved 
in formalin for histological staining, or snap frozen for biochemical analyses including oxidative 
stress and apoptosis. 
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Results: Animals exposed to the high fat diet gained significantly more weight by the end of the 
study (29.24 ± 1.99 g, p<0.0001) versus those on the standard diet (19.72 ± 0.52 g). Not only did 
these animals display increased gonadal adiposity, circulating levels of glucose and leptin were also 
elevated. Furthermore, this group of animals showed a decreased heart-to-body weight ratio and 
fibrosis when compared to their control counter parts. In the presence of a tumour (T), there was a 
considerable decline in body weight in both diet groups (S+T and H+T) when compared to the diet 
groups (S and H) alone. This study also observed a decrease in body weight when group S+T was 
compared to group H+T. Interleukin-6 (IL-6) levels were significantly augmented in group H+T 
(64.95 ± 11.62 pg/ml, p<0.01) versus group H (24.17 ± 5.59 pg/ml). While no major histological 
changes were observed in the high fat diet fed animals (H and H+T), interstitial congestion within the 
heart tissue and reduced fibrosis was evident in the standard fed group with a tumour (1.23±0.20%, 
p<0.001) when compared to the standard diet fed animals alone (2.40 ± 0.23%). When DOX (D) 
treatment was introduced to animals that received either diet, the body weight of animals fed the high 
fat diet (H+D) (25.02 ± 0.84 g, p<0.001) remained significantly higher than the animals fed the 
standard diet in the presence of DOX (S+D) (19.05 ± 0.23 g). Moreover, body weight loss was also 
observed when the high fat diet alone group (H) (29.24 ± 1.99 g) was compared to the high fat diet 
animals with tumours and treated with DOX (H+T+D) (21.30 ± 1.25 g, p<0.0001). This group of 
animals (H+T+D) also displayed significantly decreased adiposity and leptin levels, however the IL-
6 concentration was elevated (126.90 ± 34.92 pg/ml, p<0.05) when compared to group H alone (24.17 
± 5.59 pg/ml). There was no evidence of cardiovascular damage or apoptotic cell death.  
Discussion and Conclusion: It is clear from the results above that a diet high in fat contributes to 
the development of obesity and the dysregulation of adipokines inducing an inflammatory state. 
However, this inflammatory response did not have a major impact on cardiovascular health. When 
the complication of cancer arises in the context of obesity, the inflammatory state is aggravated 
due the rise in the pro-inflammatory cytokine IL-6. Although cancer is known to result in 
significant weight loss, in this context, the loss of weight, particularly fat mass may be initially 
viewed as beneficial. However if this loss of weight is sustained over an extended period of time, 
detrimental effects become evident. When DOX therapy was administered in this co-morbid state, 
it too contributed to the decrease in body weight, adiposity and leptin concentrations, while IL-6 
levels remained elevated. It is therefore possible that the weight loss observed in this study may be 
attributed to the stimulation of degradation pathways as these pathways are known to be triggered 
by inflammation and also DOX. While this study did not demonstrate considerable alterations 
Stellenbosch University  https://scholar.sun.ac.za
 iv 
 
in myocardial tissue, possibly due to the model not being severe enough to induce such changes 
in a short period oftime, this study is the first to our knowledge to develop a co-morbid model of 
obesity and cancer with chemotherapy. 
  
Stellenbosch University  https://scholar.sun.ac.za
 v 
 
OPSOMMING 
Inleiding: Vetsug is ‘n welbekende globale pandemie wat fundamenteel veroorsaak word deur ‘n 
energie wanbalans tussen kalorieë wat ingeneem en verbruik word. ‘n Hoofnagevolg van vetsug is 
metaboliese wysigings wat met insulienweerstandigheid en sentrale vetsugtigheid gepaard gaan.  Nie 
alleen is hierdie faktore verwant aan die metaboliese sindroom nie maar dit verhoog ook die risiko 
vir die ontwikkeling van kardiovaskulêre siekte.  Vetsugtigheid is onlangs verbind met die 
ontwikkeling van kanker, en meer spesifiek bors en prostaatkanker. Terwyl verskeie meganismes 
voorgestel is, is die mees bekende insulien, insulienagtige groeifaktor 1 (IGF-1), geslagshormone en 
adipokiene. Hoewel navorsing nog in ‘n vroeë stadium is om die meganismes wat onderliggend 
vetsug met kanker te verbind, is dit noodsaaklik om die prosesse van karsinogenese in vetsug 
verwante kankers te verstaan om sodoende behandelingsopsies asook voorkomende strategieë te 
ontwikkel.  Die gebruik van doksorubisien (DOX), ‘n kragtige chemoterapeutiese middel, word 
beperk deur die kumulatiewe dosis-afhanglike toksisiteit wat aanleiding kan gee tot kongestiewe 
hartversaking.  Meeste van hierdie inflammatoriese siektes is in isolasie bestudeer en daar is weinig, 
indien enige studies wat kanker en kardiotoksisiteit in die konteks van vetsugtigheid bestudeer het, 
om sodoende die komplekse verband wat hierdie siektes met mekaar deel, en hoe kardiovaskulêre 
funksie negatief hierdeur geaffekteer word te verstaan.  Hierdie studie hipotetiseer dat kanker in ‘n 
vetsugtige omgewing die risiko vir die ontwikkeling van vroeë stadium DOX-geinduseerde 
kardiotoksisiteit verhoog. 
 
Metodes: Drie-week oue vroulike C57BL6 muise is geklimatiseer en ewekansig verdeel in hoë 
vetdieet (H) of standaarddieet (S) groepe vir agtweke om sodoende vetsugtigheid te induseer. Hierdie 
groepe is verder in twee verdeel waar een groep met E0771 borskankerselle geinokuleer is en die 
ander groep as kontrole gedien het.  Die diere was verder verdeel in twee groepe die oomblik toe die 
gewasse voelbaar was met een groep wat daarna DOX ontvang het. Elke dier op behandeling het drie 
intraperitoneale inspuitings van 4 mg/kg DOX ontvang in ‘n kumulatiewe dosis van 12 mg/kg. Die 
diere is op die groepdieete gehou en daagliks gemonitor oor die verloop van die studie. Vier dae na 
die finale inspuiting is die diere geweeg gevolg deur genade dood waarna die harte gedisekteer is.  
Die bloed is versamel om sirkulerende sitokiene, adipokiene en merkers van kardiovaskulêre skade 
te ondersoek, terwyl die hart in formalien gepreserveer is vir histologiese kleuring of geklampvries 
vir biochemiese analise insluitend oksidatiewe stres en apoptose.  
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Resulte: Die diere wat blootgestel is aan die hoë vetdieet het betekenisvolle gewigstoename teen die 
einde van die studie (29.24 ± 1.99 g, p<0.0001) vergeleke met die standaarddieet (19.72 ± 0.52 g) 
getoon. Nie net het die diere ook verhoogde gonodale adipositeit gelewer nie, maar sirkulerende 
glukose en leptien is ook verhoog gewees.  Verder het hierdie groep diere verlaagde hart-tot-
liggaamsgewigverhouding en fibrose vertoon teenoor die kontrole groep.  In die teenwoordigheid van 
die tumor (T) was daar ‘n besondere afname in liggaamsgewig in beide die dieetgroepe (S+T and 
H+T) teenoor die standaardgroepe alleen (S and H). Hierdie studie het ‘n afname in liggaamsgewig 
tussen groep S+T teenoor groep H+T waargeneem. Interleukien-6 (IL-6) vlakke het betekensivol 
verskil in groep H+T (64.95±11.62 pg/ml, p<0.01) teenoor groep H (24.17±5.59 pg/ml). Terwyl geen 
histologiese veranderinge waargeneem is in die hoë vetdieet diere nie (H en H+T), is interstisiëele 
kongestie en verlaagde fibrose in die standaarddieet groep met die tumor waargeneem (1.23±0.20%, 
p<0.001), vergeleke met die standaarddieet groep diere (2.40±0.23%). Tydens die aanvang van DOX 
(D) behandeling is daar in beide dieetgroepe op die hoë vetdieet (H+D) (25.02±0.84 g, p<0.001) ‘n 
betekenisvolle verhoging waargeneem vergeleke met die standaarddieet groep in die teenwoordigheid 
van DOX (S+D) (19.05±0.23 g). Liggaamsgewig verlies is waargeneem in die hoë vetdieet alleen 
groep (H) (29.24±1.99 g) teenoor die hoë vetdieet groep diere met die tumor en wat met DOX 
behandel is (H+T+D) (21.30±1.25 g, p<0.0001). Hierdie groep diere (H+T+D) het ook betekensivolle 
verlaagde adipositeit en leptienvlakke vertoon hoewel die IL-6 konsentrasie verhoog was (126.90 ± 
34.92 pg/ml, p < 0.05) vergeleke met die H groep alleenlik (24.17 ± 5.59 pg/ml). Daar is geen bewyse 
vir kardiovaskulêre skade of apoptiese seldood nie. 
 
Bespreking en gevolgtrekking: Dit is duidelik uit hierdie resultate dat ‘n hoë vetdieet bydra tot the 
ontwikkeling van vetsug en die disregulering van adipokiene en die inflammatoriese toestand.  
Hierdie inflammatoriese respons het nie ‘n groot impak op kardiovaskulêre gesondheid gehad nie.  
Wanneer kanker in ‘n vetsugtige konteks ondersoek word, het die inflammatoriese toestand vererger 
as gevolg van die toename in die pro-inflammatoriese sitokien IL-6. Hoevewel kanker gewoontlik 
met gewigsverlies geassosieer word, kan die gewigsverlies wat in hierdie konteks waargeneem is, 
veral vetmassa, aanvanglik voordelig wees.  Indien hierdie gewigsverlies oor ‘n langer tydperk 
gehandhaaf word kan dit as nadelig en gevaarlik beskou word.  Wanneer DOX terapie toegedien word 
in die ko-morbiede stadium het dit self bygedra tot die verlies aan liggaamsgewig, adipositeit en 
leptienkonsentrasies, terwyl IL-6 vlakke verhoog was.  Dit is dus moontlik dat die gewigsverlies wat 
in hierdie studie waargeneem is bydraend tot die stimulering van degraderingspadweë, en dat hierdie 
wëe ook deur inflammasie en DOX gestimuleer is. Alhoewel hierdie studie nie merkbare 
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veranderinge in die miokardiale weefsel kon demonstreer nie, omrede die model in ‘n relatief kort 
periode nie die skade kan veroorsaak nie, het die studie wel daarin geslaag om ‘n nuwe ko-morbiede 
model van vetsug, kanker en chemoterapie te beskryf. 
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STAT   Signal transducer and activator of transcription proteins 
S+T+D  Standard diet + Tumour + Doxorubicin group 
S+T+V  Standard diet + Tumour + Vehicle control group  
S+V   Standard diet + Vehicle control group 
T2DM   Type 2 Diabetes Mellitus 
TBA   Thiobarbituric acid 
TBARS  Thiobarbituric Acid Reactive Substances 
TBS-T   Tris-buffer saline Tween 20 
TG    Triglyceride 
TNF-α   Tumour necrosis factor alpha 
WAT   White adipose tissue 
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UNITS 
µg : microgram 
mg : milligram 
g gram 
kg : kilogram 
nM: nanomolar 
μM : micromolar 
mM: millimolar 
M: molar 
nm : nanometer 
µm: micrometer 
mm millimeter 
mm2 millimeters squared 
mm3 millimeters cubic 
μL Microliter 
mL milliliter 
L litre 
pg/ml Pictogram per milliliter 
ng/mL nanogram per milliliter 
mg/mL milligram per milliliter 
g/mL gram per milliliter 
mmol/L millimole per liter 
µmol/gram micromole per gram 
mg/m2 milligram per meter squared 
μg/kg microgram per kilogram 
mg/kg milligrams per kilogram 
kg/m2 kilogram per meter squared 
v/v% volume in volume percent 
Amps Ampere 
AU Arbitrary Units 
ºC degrees Celsius 
V Volt 
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% percentage 
kcal Kilocalorie 
kDa Kilo Dalton 
mA Milli-ampere 
Hrs hours 
Mins minutes 
Secs seconds 
rmp Rate per minute 
1º Primary 
2º Secondary 
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1. LITERATURE REVIEW 
1.1  Obesity in context 
1.1.1  Obesity defined 
While being overweight or obese has previously been considered a serious health problem, it is 
now considered a global pandemic. The worldwide prevalence of obesity was almost doubled 
in the 1980s and tripled by 2016 in adults and children respectively (Segal et al., 2017). In the 
same year, approximately 13% of the world’s adult population (11% of men and 15% of 
women) were obese, whereas an estimated 41 million children under the age of five years were 
deemed obese or overweight. It was previously thought that this condition occurred in high-
income countries, however it is now prevalent in low- to middle-income countries as well, 
particularly in the urban and peri-urban regions. In Africa, the number of overweight children 
under the age of five has risen by nearly 50% since 1990s (WHO, 2017).  
Being overweight or obese is defined as an excessive accumulation of fat that may impair 
overall health. This excessive accumulation fat, known as adiposity, is due to increased food 
intake which is then stored in adipose tissue (Lin et al., 2000). Clinically, obesity is measured 
by the determination of the body mass index (BMI), a simple index of weight-to-height measure 
in kilograms/meter squared (kg/m2). An individual is considered overweight if their BMI is 
equal to or greater than 25 kg/m2, whereas an obese individual has a BMI of equal to or greater 
than 30 kg/m2 (Ford et al., 2011). Although BMI provides the most useful population measure 
of being overweight or obese as it is the same for both males and females, it should be 
considered as a guide because it may not correspond to the same degree of ‘fatness’ in different 
individuals especially in the context of gender. 
Other useful measures of determining whether an individual is overweight or obese include the 
waist to hip ratio and waist circumference, which are often used alongside BMI for a more 
holistic indication of where excessive fat is stored within the body. More sophisticated 
techniques such as underwater weighting, x-ray absorptiometry have also been established, 
however they require specialised equipment resulting in these techniques being expensive and 
thus traditional measurements are often adhered to (Deurenberg, 1999; Leopoldo et al. , 2016). 
Apart from establishing ways to diagnose obesity it is also important to understand the risk 
factors that are associated with this disease state. 
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1.1.2  Epidemiology of obesity  
There are numerous causes for the development of obesity, however the fundamental cause is 
an energy imbalance between calories consumed and calories expended (Mraz & Haluzik, 
2014). Simply put, if one consume more calories than one expend, one gains weight, and if more 
calories is used than consume then weight is lost. It should be bared in mind that this does not 
take into account the types of calories individuals ingest which is important in terms of the 
balance between carbohydrates, proteins and fats. Globally, there has been an increased intake 
of energy-dense foods that are high in unsaturated fats mainly due to affordability, followed by 
a decrease in physical activity (Finkelstein et al., 2005). This may be due to various factors 
namely:  
 (i) Environment: the sedentary nature of many forms of work, changing modes of 
transportation, and the rise in urbanization, 
 (ii) Behaviour: increased physical inactivity, the selection of economically cheaper and 
palatable food and socio-cultural behaviour and, 
 (iii) Physiology: the energy imbalance due to lifestyle choices of the individual, as well 
as genetic predisposition (Swinburn et al., 2011, Hruby & Hu, 2015).  
Although the above mentioned factors play an important role in this context, the genetic 
contribution to this state cannot be ignored (Albuquerque et al., 2015). More often than not, it 
has been documented that obesity appears to occur more in families where some family 
members are already obese, or are born from parents who were or are currently obese. In support 
of this theory, Reilly et al., (2005) demonstrated that the odds in children being obese increased 
to 2.93%, 4.66% and 11.75% if the father, mother or both parents respectively were obese, thus 
signifying a dominant influence of parental obesity. Moreover, parental obesity is deemed 
better to predict obesity during adulthood than the child's own weight status (Fuemmeler et al., 
2013). Interestingly, in an obesity-conducive environment, genetic factors influence the 
propensity of a child to becoming obese. Leptin deficiency, hypothyroidism, growth hormone 
deficiency or side effects associated with drugs such as steroids, have all been shown to 
contribute to childhood obesity  (Güngör, 2014). Some of the common antenatal and postnatal 
factors thought to influence childhood and adulthood obesity include gestational diabetes 
mellitus, maternal weight gain during pregnancy, intra-uterine growth retardation, babies that 
are either too small or too large for gestational age, early bottle feeding, infant over nutrition 
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and early adiposity. It should be mentioned however that the above conditions do not influence 
childhood or adult obesity more than personal lifestyle choices as well as environmental and 
behavioural factors. Figure 1.1 below illustrates the factors already discussed that have an 
established role in obesity and other factors that will not be discussed as part of this literature 
review. 
 
 
 
Figure 1.1: Causes of childhood and adulthood obesity. Obesity is a multifactorial disease 
and usually consists of many factors that interact and contribute to the condition based on 
genetic predisposition, lifestyle choice, environmental and behavioural factors. 
 
1.1.3  Consequences of obesity on health status 
A major consequence to obesity as defined by the National Heart, Lung, and Blood Institute, 
are metabolic perturbations accompanied by insulin insensitivity (which makes it difficult to 
utilise blood glucose), and central obesity (excess fat around the abdominal and stomach area 
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of the body). These factors are often associated with metabolic syndrome, a condition defined 
as abnormalities in three or more of the following: waist circumference, fasting blood 
triglycerides, cholesterol levels, blood pressure and fasting glucose levels (Aggoun, 2007). 
Together, these factors have a long-term risk of cardiovascular disease (CVD) and type 2 
diabetes mellitus (T2DM) (Kahn & Flier, 2000; O’Neill & O’Driscoll, 2015) and ultimately 
impacts on the quality of life as health is compromised. 
1.2 The heart  
1.2.1 Myocardial metabolism 
The heart is a four chambered organ (two ventricles and two atriums) and together with the 
lungs are responsible for the replenishment of oxygen rich blood to various organs in the body 
(Figure 1.2). As this organ plays a critical role in maintaining blood circulation, it requires a 
high demand of energy (ATP) output provided by the abundant mitochondria present (Marieb 
& Hoehn, 2013). The heart’s metabolic machinery consists of three components: (i) substrate 
utilization, (ii) the breakdown of substrates by mitochondria to produce energy and, (iii) the 
transfer of the energy and utilization thereof in maintaining myocardial function (Scolletta & 
Biagioli, 2010). Under normal conditions the main substrate utilized by mitochondria are fatty 
acids and followed by pyruvate (Stanley & Chandler, 2002; Kolwicz et al., 2013). The heart 
has a wide scope and flexibility in using other substrates including carbohydrates, amino acids 
and ketone bodies to allow for its 24/7 contractile function (Kolwicz et al., 2013). The 
importance of a switch in substrate utilization is demonstrated through different scenarios that 
require the heart to work harder (e.g. exercise) or, during times of nutrient stress (e.g. fasting) 
or, when the myocardium becomes damaged because of disease. Depending on the type, 
severity and duration of the stress, the shift in substrate utilization can be temporary (adaptation) 
or long-term (maladaptation). Table 1.1 depicts the different substrates utilized under various 
conditions and shows how the heart switches from one substrate to another. 
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Figure 1.2: The anatomical structure of the heart showing the ventricles and atriums. 
The structural display of the hearts anatomical layout four chambered heart, two ventricles (left 
and right) and two atriums( left and right),obtained from Marieb & Hoehn, 2013. 
 
Table 1.1: Different substrates utilized by the heart under various conditions 
(Adapted from Stanley & Chandler, 2002; Harmancey et al., 2008; Kolwicz et al., 2013; 
Ritterhoff & Tian, 2017)  
Condition Short Explanation Main Substrate 
Foetus Heart 
- Normal contractile function and cardiac 
output in developing heart under low oxygen 
environment 
Glucose 
Lactate 
Normal Adult heart 
- Normal contractile function and cardiac 
output 
Free Fatty Acids 
Glucose 
Exercise 
- Increased energy, blood flow and oxygen to 
skeletal muscles 
Lactate 
Fasting/Starvation 
- Low glucose presence and glycogen stores 
are used up 
Ketone Bodies 
Amino Acids 
Ischemia - Area in heart that no longer functions 
Glucose 
Ketone bodies 
Diabetes/Obesity 
- Decrease in oxidative metabolism resulting 
in increased oxidative stress, 
insulin resistance, lipid accumulation and 
energy depletion 
Glucose 
 
Left 
Atrium 
Left 
Ventricle 
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1.2.2  Myocardial adaption and maladaptation during obesity 
As mentioned previously, under normal conditions, the heart utilizes fatty acids as the main 
substrate for energy production, but during heart failure for example, glucose and lactate are 
used (Stanley & Chandler, 2002). During this state, the adult heart is said to mimic the foetus 
heart, and although not completely understood, it is believed that since fatty acid metabolism 
utilizes more energy that glucose metabolism, the anaerobic glycolysis that takes place is a 
more energy efficient mechanism for generating energy to maintain cardiovascular function 
(Schulze, 2009). 
While fat in the body is often associated with negative connotations, it is an essential substrate 
particularly with reference to white adipose tissue (WAT). Not only is it responsible for the 
management and storage of excess lipid triglycerides (Vázquez-Vela et al., 2008), it functions 
as a paracrine and endocrine organ that has an interactive role in the secretion of adipokines. 
Even though adipokines are circulating hormones that communicate with other organs to 
maintain energy balance (adiponectin) and food intake (leptin) (Lau et al., 2005), their 
dysregulation has been implicated in inflammatory conditions that have been shown to induce 
peripheral insulin tissue resistance and CVD (Kwon & Pessin, 2013). In obese individuals and 
rodent models, the expression of pro- to anti-inflammatory adipokines is at least in part 
augmented to induce insulin resistance. Collectively, these findings suggest that not only is 
there malfunction in the paracrine and endocrine secretions of WAT, obesity-related insulin 
resistance may result from an imbalance between the expressions of pro- and anti-inflammatory 
adipokines. Together with the increase in adipose tissue, a state of hypoxia is induced which 
results in a switch of WAT from a storage organ to an actively secreting organ. This 
dysregulation is thus believed to be one of the causes of obesity-induced T2DM, dyslipidaemia, 
CVD and cancer (Fernández-Sánchez et al., 2011).  
1.3 Mechanisms that link obesity to cardiovascular damage 
1.3.1 Cardiac remodelling of the heart  
Under obese conditions, there is an increase in body fat which augments cardiac output and 
blood volume (Marieb & Hoehn, 2013). To compensate for this change, the heart requires a 
bigger output rate supplied by the change in the hearts preload. Although this change may 
initially be an adaptive mechanism, over time this adaptation can be maladaptive as left 
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ventricular remodelling with enlargement of the ventricle occurs (Harmancey et al., 2008). The 
increased tension that arises in the left ventricular wall eventually culminates in left ventricular 
hypertrophy. Considering that obesity leads to other disorders, further damage to the heart is 
almost inevitable.  
Cardiomyocytes are the most abundant cells contained in the heart and have a low regenerative 
capacity (Sawyer et al., 2010; Kikuchi & Poss, 2012). When irreversible damage occurs, 
activated fibroblasts in the heart deposit collagen to replace the dead or dying cells. This 
deposition of collagen is known as fibrosis (Mahajan et al., 2015). The consequence of this 
results in a decrease in the number of cardiomyocytes and thickening of the ventricular wall. 
Furthermore, since fibroblasts lack the flexibility of cardiomyocytes, myocardial contractility 
is reduced due to the stiffness of the myocardium. The above changes demonstrate a 
phenomenon known as cardiac remodelling which has been established in many preclinical 
research models (Abel et al., 2008, Calligaris et al., 2013; Russo & Frangogiannis, 2016). 
Leopoldo and colleagues (2016) illustrated insulin resistance, hyperleptinemia, collagen 
deposition and ultrastructural changes of the myocardium in rats fed a high fat diet over a period 
of 15 weeks. It is therefore clear to see how the state of obesity induced by diet over time 
negatively impacts on normal cardiovascular function. 
Other mechanism by which obesity can contribute to cardiac remodeling is the high blood 
glucose occurs. The toxic effect of the overabundance of fasted blood glucose term 
glucotoxicity has been linked to the symptom associated with the development of heart failure 
(Chess & Stanley, 2008). The over-expression of glucose becomes toxic to the heart and 
activates various pathways and downstream mechanisms. Hyperglycemia induces ROS 
production and this causes mitochondrial dysfunction and fragmentation. Since there is a shift 
in substrate utilization, AMP-activated protein kinase (AMPK) mediates metabolic adaptation 
under stress conditions by inhibiting energy-consuming pathways. It stimulates both FA 
oxidation and glycolysis to produce ATP whilst reducing ATP consuming processes (anabolic 
pathways). AMPK forms part of the mechanism to preserve energy under stressful conditions. 
The depletion of ATP or the ability to produce sufficient ATP eventually lead to the 
downstream  activation of pathways are directly associated with signaling mechanisms 
associated with mitochondrial dysfunction and ROS production and thus cause damage within 
the heart. Hyperglycemia is able to promote the fibrogenic phenotype and the activation of the 
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inflammatory state (Russo & Frangogiannis, 2016). All these known pathways can contribute 
to how obesity causes damage to the heart. 
1.3.2 Stages of heart failure 
Heart failure (HF) is define as the inability of the heart to function effectively and affects the 
pumping ability of the heart; it is strongly associated with chronic shift in substrate utilization 
often associated with metabolic disease. The heart is an insulin-responsive organ and therefore 
and insensitivity to insulin associated with diabetes can lead to glucotoxicity and shift in the 
metabolic state of the heart which is how diabetes cardiomyopathy can occur (Riehle & Abel, 
2016). Clinically HF it is classified by four different stages according to the (NYHA, 2019). 
Clinicians classify patients due to the severity of symptoms and signs of heart disease as 
follows. Stage 1: showing risk factors of heart failure development but no heart disease and 
symptoms, Stage 2: Heart disease and no structural changes or symptoms, Stage 3: structural 
heart disease and mild symptoms and Stage 4: advanced heart disease with heart failure 
symptoms and patients’ require therapy and treatment. Although various symptoms and causes 
can affect the heart the end-point stage 4 when heart failure occurs becomes life threating as 
the heart has lost most of its functionality. 
 
1.4 Lipid accumulation and the development of insulin resistance  
A distinct feature of obesity is the excessive accumulation of circulating free fatty acids (FFAs) 
in the blood. These FFAs are thought to bring about the onset of insulin resistance (IR) which 
is a feature of obesity and other metabolic diseases associated with obesity (Boden, 2011). 
Under normal conditions insulin signaling is involved in the regulation of blood glucose 
transport and storage, as well as the maintenance of lipolysis; however when insulin is down-
regulated, IR ensues  (Boden, 2011). As such, a few theories have been proposed that link fat 
accumulation due to diet-induced obesity (DIO) to the development of IR. Firstly, when there 
is an increase in free FFAs in a cell, these generate reactive oxygen species (ROS) and 
diacylglycerol (DAG) which go on to stimulate the serine/threonine protein kinase C (PKC) 
cascade. This cascade is responsible for the phosphorylation and activation of the insulin 
receptor substrate (IRS-1) at its threonine residue. However, under these conditions, it is the 
serine residue that gets phosphorylated which inhibits the activity of the PI3K/Akt (PKB) 
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pathway responsible for the translocation of glucose receptors (e.g.: GLUT 4) onto the cell 
membrane (Petersen & Shulman, 2006). Secondly, obesity is an inflammatory condition and is 
therefore is associated with an elevated concentration of pro-inflammatory cytokines. These 
include tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), both of which are 
known to inhibit the action of insulin. Not only are these cytokines upregulated with chronic 
inflammation and conditions of muscle wasting, their stimulation of immune and inflammatory 
responses occurs through nuclear factor kappa light chain enhancer of activated B cells (NFκB) 
(Riehle & Abel, 2016b). Which will induce the transcription of genes involved in cell death and 
protein degradation (Sishi et al., 2013). Thirdly, the failure of packaging excess lipids into lipid 
droplets can be toxic to non-adipose tissue. The deleterious effects of lipid accumulation in non-
adipose tissue is known as lipotoxicity (Wende & Abel, 2011). Interestingly, triglycerides can 
also serve as a storage facility for long chain non-esterified fatty acids (NEFAs) as well as their 
products including ceramide and DAG. Therefore, within the scope of lipotoxicity, it can be 
concluded that excess saturated fatty acids, DAG and ceramide in obesity can induce chronic 
adipose tissue inflammation, IR and mitochondrial dysfunction, all of which have a harmful 
effect on multiple organs and systems in the body. 
1.4.1 Oxidative stress and mitochondrial dysfunction in context 
As mentioned previously, myocardial tissue is particularly vulnerable to oxidative damage 
more than any other tissue due to its high oxidative environment and limited antioxidant 
defenses. Moreover, one third of the hearts weight is comprised of mitochondria (Kolwicz et 
al., 2013; Octavia et al., 2012). ROS is an unavoidable consequence to ATP production and 
when a state of oxidative stress occurs, the antioxidant systems in the heart become 
overwhelmed by the free radicals that are produced. If the stress is moderate, senescence or cell 
cycle inhibition takes place; however if the stress is severe, apoptosis and/or necrosis can be 
initiated (Carvalho et al., 2013). The onset of apoptosis results from lipid peroxidation of 
mitochondrial membrane phospholipids which causes a collapse in the mitochondrial 
membrane potential, the opening of the mitochondrial membrane permeability transition pore 
(mPTP), cytochrome c leakage and downstream caspase-3 activation (Webster, 2012; Kubli, & 
Gustafsson, 2012). The end result for the heart is a reduced capacity to generate energy and in 
the long term, the heart will fail. 
The most prominent role for mitochondria is to supply energy in the form of ATP during 
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oxidative phosphorylation. Furthermore, mitochondria are involved in a vast array of anabolic 
and catabolic processes, and are required for the assembly of iron-sulphur clusters, which are 
essential cofactors of many enzymes (Stehling & Lill, 2013). In addition to their role in different 
biochemical pathways, mitochondria regulate apoptosis and participate in the process of 
development and ageing (Gustafsson & Gottlieb, 2006). Therefore, mitochondrial integrity is 
vital for cardiomyocyte function and two opposing processes collectively termed as 
mitochondrial dynamics maintain this integrity (Hom & Sheu, 2009). Mitochondria constantly 
fluctuate between fusion (fuse) and fission (divide) events which regulate the length of these 
organelles as well as their degree of interconnectivity. The rate at which these events happen is 
influenced by metabolic and pathological stimuli within mitochondria and the surrounding 
cellular environment (Westermann, 2010). The antagonistic and balanced actions of the fusion 
and fission machinery shapes mitochondria and through the dynamic nature of these organelles, 
allows cells to respond to the ever-changing physiological hues. On the one hand, a shift 
towards fusion promotes the generation of interconnected mitochondria which is beneficial in 
metabolically active cells, however on the other hand, a shift towards fission favors 
mitochondrial fragmentation which considered detrimental (Westermann, 2010). Not only are 
fusion and fission events important for growth, mitochondrial redistribution and maintenance 
of a healthy mitochondrial pool, they play a critical role in disease-related processes such as 
apoptosis and mitophagy (mitochondrial specific degradation via autophagy) (Kubli & 
Gustafsson, 2012). Autophagy is defined as cellular process involved in self-cannibalization 
and involves the promotion of both cell survival and cell death activation (Rabinowitz & White, 
2010) 
1.4.2 Adipokines and the heart  
Adipokine secretion plays a role in insulin sensitivity, the regulation of food intake and energy 
homeostasis of the body under normal conditions (Guerre-Millo, 2008). During obesity, 
adipokines are considerably elevated and in this manner are considered dysregulated (Lau et 
al., 2005). Their increased levels have been linked to the stimulation of pathways involved in 
oxidative stress and inflammation by endocrine, paracrine and autocrine systems. The longer 
the inflammation continues, the higher the risk of damage. Generally, two stages of 
inflammation exist: acute and chronic. Acute inflammation constitutes the initial stage of 
inflammation and is regulated through the activation of the innate immune system. This type of 
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inflammation is short-lived (temporary) and is usually beneficial to the host. If inflammation 
persists, the second stage of inflammation, or chronic inflammation is initiated, and this 
predisposes the host to various chronic illnesses (Lawrence & Gilroy, 2007). During this event, 
inflammatory cells such as mast cells and leucocytes are deployed to the site of injury, which 
leads to a ‘respiratory burst’ due to the increased consumption of oxygen, and therefore an 
increased release and accumulation of ROS is expected (Saeidnia & Abdollahi, 2013). It is for 
this reason that inflammation and oxidative stress cannot be easily separated.  
Leptin, an adipokine encoded by ob gene and secreted by adipose tissue, is involved in the 
regulation of body weight on the bases that it modulates food intake and energy expenditure 
through the stimulation of neurotransmitters in the hypothalamus (Lau et al., 2005; Schäffler & 
Schölmerich, 2010). In pathological conditions such as obesity, the balance of leptin actions 
may shift to stimulate inflammation, oxidative stress, and smooth muscle hypertrophy. These 
actions may contribute to the pathogenesis of hypertension, atherosclerosis, left ventricular 
hypertrophy, and T2DM (Deswal, 2011). Under these conditions, elevated levels of leptin are 
observed due to the disruption of the leptin signalling cascade within the central nervous system 
(CNS). Therefore, the maintenance of energy balance is impaired which results in the body 
becoming insensitive to leptin, or otherwise leptin resistant. This resistance allows for leptin 
levels to rise in blood circulation and correlates with an individual’s BMI (Maskari & Alnaqdy, 
2006). While numerous investigation have been conducted to understand the importance of 
leptin in obesity-related CVD, hyperleptinaemia has been confirmed to be a predictor of acute 
cardiovascular events (Hou & Luo, 2011). 
In contrast, adiponectin, the most abundant adipokine secreted by adipocytes appears to have 
an opposing effect to the above mentioned adipokine in obesity. Not only is it also responsible 
for energy homeostasis, it possesses anti-inflammatory effects and improves insulin sensitivity 
(Fernández-Sánchez et al., 2011). Although its cardioprotective role has been well studied, 
clinical investigations have identified adiponectin deficiency (hypoadiponectinaemia), or the 
down-regulation thereof, as seen during obesity or related pathologies, as an independent risk 
factor for CVD (Singla et al., 2010). The up-regulation of adiponectin both genetically or 
pharmacologically, has been illustrated to improve obesity-induced endothelial cell dysfunction 
and hypertension, and also prevents atherosclerosis, myocardial infarction and diabetic 
cardiomyopathy (Ouchi et al., 2006; Shibata et al., 2009; Hui et al., 2012). While the exact 
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mechanisms are yet to be fully elucidated, it is speculated that adiponectin protects 
cardiovascular health through its vasodilatory, anti-apoptotic, anti-inflammatory and anti-
oxidative properties in both cardiac and vascular cells (Hopkins et al., 2007; Shibata et al., 
2009;  Hui et al., 2012). Based on the above literature, it is clear to see the importance of 
adipokines in maintaining cardiovascular health. 
1.4.3 Pro-inflammatory cytokines (other adipokines) 
Some adipokines are also classified as cytokines since they are secreted by not only adipocytes 
but also other cell types. These include interleukin-6 (IL-6) and tumour necrosis factor-alpha 
(TNF-α). TNF-α plays a major role in a broad range of diverse actions which include growth 
and differentiation (Kirillova et al., 1999), inflammation (Schutz et al., 1992), apoptosis and 
necrosis (Basu et al., 2002). IL-6 is produced in response to host infections and tissue injury by 
contributing to the stimulation of acute phase responses, haematopoiesis and immune reactions 
(Tanaka et al., 2014). Although these cytokines function pleiotropically (anti- and pro-
inflammatory), their expressions are transcriptionally and post translationary controlled, and 
their dysregulated synthesis plays a pathological role in chronic inflammation and 
autoimmunity (Ishihara & Hirano, 2002). Over the past decades, it has become evident that 
excess adipose tissue gives rise to chronic, low grade inflammation, which plays a significant 
role in the development of obesity and associated disorders such as insulin resistance, T2DM, 
metabolic syndrome and CVD (Lau et al., 2005; Singla, 2010; Boden, 2011; Hsieh, 2011). 
Under these conditions, WAT secretes increased levels of TNF-α and IL-6 which may not only 
have local effects on WAT, but also systemic effects on other organs (Ronti et al., 
2006;Vázquez-Vela et al., 2008). While TNF-α in adipose tissue plays a central role in lipid 
metabolism and insulin regulation, IRS-1 activity is prohibited during obesity. Additionally in 
this context, IL-6 is implicated to play a central role between obesity and inflammation as it 
promotes the accumulation of FFAs  (Fernández-Sánchez et al., 2011; Wueest et al., 2014).  
There is a growing concern that this prolonged pro-inflammatory state and the dysregulation of 
adipokines within obese individuals, serves as the ideal micro-environment for the cancer cells 
to thrive. For a normal cell to evolve into a cancerous one, it requires specialized events for the 
transition to take place. Each cell is equipped with controlling genes responsible for surveillance 
and to suppress the initiation and progression of pro-neoplastic cells (Hanahan & Weinberg, 
2000). Since the metabolic state of the body is used as a source of survival for cancer cells, 
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obesity provides a “scape goat” for these cells to surpass these check points because of its effect 
on metabolic regulation. Recent research has found that as BMI increases by 5 kg/m2, the 
incidence of cancer increases by 10% (Basen-Engquist & Chang, 2011). The link between 
obesity and cancer has been demonstrated in numerous cohort studies (Basen-Engquist  & 
Chang, 2011; Matthews & Thompson, 2016) and the percentages of cancer attributed to obesity 
were 11% for colon cancer, 9% for post-menopausal breast cancer, 39% for endometrial cancer, 
25% for kidney cancer and 37% for oesophageal cancer (Basen-Engquist & Chang, 2011). In 
an effort to understand the link between obesity and cancer risk, current studies are focused on 
the mechanisms involved. However, due to the complex nature of obesity and the numerous 
mechanisms involved, which may differ across cancer sites, various pathophysiological 
mechanisms have been proposed and will be discussed in the next section. 
1.5 Mechanisms underlying the obesity-cancer link 
While numerous mechanisms have been proposed, a comprehensive summary of all possible 
systems is beyond the scope of this review, and thus only the most relevant and emerging 
processes linking obesity to carcinogenesis will be highlighted. 
1.5.1 Insulin, IGF-1 and IGFBPs 
By far the biological mechanisms that have received much attention include insulin, insulin-
like growth factor-1 (IGF-1), sex hormones and adipokines. It is well known that during obesity, 
a state of hyperinsulinemia occurs and works by preventing apoptosis and promotes cell 
proliferation. The augmented levels of insulin in this scenario reduces IGF binding proteins 
(IGFBPs) which then leads to increased IGF-1 levels, a change in the cellular environment and 
ultimately tumour growth (Calle & Kaaks, 2004). Coincidentally, insulin also regulates growth 
hormone which in turn contributes to the production of IGF-1 and IGFBP-3 (Nam et al., 1997). 
Even though studies measuring IGFBP-3 have been inconsistent, elevated levels of IGF-1 have 
been associated with an increased risk of pre- and post-menopausal breast cancer and prostate 
cancer (Shanmugalingam et al., 2016). 
1.5.2 Hormone dependent cancers 
There is growing evidence to support the role of the effect of sex hormones and their link 
between these two inflammatory conditions, particularly those that are considered to be 
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hormone dependent (e.g.: breast, ovarian uterine and prostate) (Folkerd & Dowsett, 2010). Sex 
hormones are mainly produced by steroidegenic organs and constitute estrogens, androgens and 
progestogens. The binding of estrogen to its receptor (ER) triggers intracellular signalling 
pathways that initiate cell division and tumour progression (Brown & Simpson, 2014). 
Moreover, excess aromatase secreted from adipose tissue leads to elevated levels of estradiol 
not being bound which damages DNA. Interestingly, adipose tissue can also act as reservoir for 
carcinogens and xenochemicals where the release thereof can contribute to carcinogenesis 
(Hsieh, 2011). 
1.5.3 Adipokine dysregulation 
As has been previously established, leptin during obesity is up-regulated whilst adiponectin is 
down-regulated. The abnormal secretion of these adipokines, as well as the pro-inflammatory 
state that is induced (Figure 1.3), has been associated with the proliferation and survival of 
cancer cells through the activation of the RAS/RAF-MAPK signalling pathway and the 
suppression of anti-inflammatory events respectively (Hsieh, 2011). In addition, IL-6 which is 
increased during obesity, promotes cell survival via the JAK/STAT signalling pathway 
(Bromberg & Wang, 2008). While colon, prostate and breast cancers have been liked with 
elevated leptin levels, adiponectin has been negatively associated with these cancers (Nalabolu, 
Palasamudram & Jamil, 2014).  
Other mechanisms linking obesity to cancer that deserve mentioning but will not be elaborated 
on, include: obesity-related hypoxia, genetic susceptibility, adipose stromal cell migration, 
inflammation and oxidative stress (Van Kruijsdijk et al., 2009; Bilić, 2014; National Cancer 
Institute, 2017). These factors point toward the relationship between adipose tissue hypoxia, 
and the development of insulin resistance that stimulates reduced adiponectin and exaggerated 
leptin gene expressions. While research on the biological mechanisms underlying obesity and 
its relationship with cancer are still in the early stages, understanding the processes of 
carcinogenesis in obesity-related cancers may lead to the development of treatments and better 
preventative strategies. 
Stellenbosch University  https://scholar.sun.ac.za
 15 
 
 
Figure 1.3: Mechanisms by which obesity causes the dysfunction of adipokines and 
how it causes carcinogenesis. Process takes places via the activation of cell proliferative 
and survival pathways induced by irregular adipokine secretion and pro-inflammatory 
cytokines (adopted from Hsieh, 2011). 
 
1.6 Anthracycline chemotherapeutic treatment 
Anthracyclines (ANTs) are a class of anti-neoplastic antibiotics extracted from Streptomyces 
bacterium (Malhotra & Perry, 2003) and are used for the treatment of various cancers including 
lymphomas and leukaemias, breast, ovarian, prostate, stomach, uterine, bladder and paediatric 
cancers (Šimůnek et al., 2009). These chemotherapeutic agents are thus among the most potent 
anti-cancer treatment regimens ever developed, and are effective against more cancer types than 
any other chemotherapeutic agent (Šimůnek et al., 2009). Although the advances in cancer 
treatment has brought hope to patients against a disease that was previously thought to be 
incurable, their life threatening side effects cannot be ignored. As indicated in Figure 1.4, 
Doxorubicin (DOX), Daunorubicin, Epirubicin and Idarubicin are the four different anti-cancer 
agents belonging to the class of ANTs. Structurally, these drugs look similar in that they contain 
a tetracyclic ring which makes up the aglyconic moiety, and a sugar moiety known as 
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daunosamine. However, what differentiates these ANTs from one other are the modifications 
in the side groups attached to the tetracyclic ring (McGowan et al., 2017). These minor 
differences are said to be responsible for their different levels of potency.  
Figure 1.4: Different antracycline classes used in the treatment of various cancers. 
Structurally, they all contain a tetracyclic ring which makes up the aglyconic moiety and a sugar 
moiety. The variation in the side chains of the aglyconic moiety differentiates them from one 
another. Orange circles distinguish between doxorubicin and daunorubicin, while yellow circles 
distinguishes between epirubicin and idarubicin (obtained from Šimůnek et al., 2009). 
 
DOX, isolated in the 1960s, forms part of the first line chemotherapeutic treatment regimens 
for many cancers and is marketed as Adriamycin® or Rubex® among other names (Takemura 
& Fujiwara, 2007; Puma et al., 2008; Zhu et al., 2010; Octavia et al., 2012). DOX affects cancer 
cell proliferation through DNA intercalation because of its binding affinity to Topoisomerase 
II. Topoisomerase II induces single and double stranded DNA breaks during DNA replication 
and once the process is complete, these breaks can be resealed again. DOX exploits this function 
by stabilizing topoisomerase II in a specific conformation when DNA is cut. This causes DOX-
DNA crosslinks which prevents DNA from being resealed, the repair process is thus halted and 
consequently cell death is induced. Another known mechanism by which this anti-cancer agent 
kills actively replicating cells is oxidative stress which causes oxidative damage to DNA, 
 
 
 
 
  
 
 
 
 
Aglycone moiety 
Sugar moiety 
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proteins and lipids (Table 1.2). Once DOX enters the cell it undergoes a one electron reduction 
leading to the formation of an unstable DOX metabolite which is in turn converted back to 
DOX. This continuous redox cycling results in the production of oxygen derived free radicals 
(Thorn et al., 2012). The ROS generated contributes to DNA alkylation, protein oxidation and 
lipid peroxidation, all of which can trigger different cell death modalities (Carvalho, 2013; 
Sawyer et al., 2010).  
Unfortunately, DOX’s potent anti-tumour effects are overshadowed by its adverse influence on 
other organs especially the myocardium. This condition is termed cardiotoxicity and is a major 
setback to the considerable progress made in the field of oncology (Minotti et al., 2004; 
Schimmel et al., 2004). The toxic effects exhibited are attributed to DOX’s cumulative and 
dose-dependent damage that leads to irreversible changes in the heart that manifests as left 
ventricular dysfunction and congestive heart failure (Chen et al., 2007;Montaigne et al.,  2012). 
In the hopes of reducing and preventing these detrimental consequences, a number of initiatives 
have been tried and tested. These include: liposomal DOX formulations (Sawyer et al., 2010) , 
anti-oxidant therapy (Schimmel et al., 2004), reduced treatment dosages as well as life time 
cumulative doses (Gianni et al., 2008), to name but a few. However despite these efforts, 
cardiotoxicity still remains clinically relevant and some of these interventions risk treatment 
efficacy and chemotherapy resistance (Housman et al., 2014).  
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Table 1.2: Mechanisms by which DOX mediates its anti-cancer actions 
(adopted from Carvalho et al., 2013) 
Anti-cancer mechanism Pathway effected Outcomes 
DNA intercalation, cross-
linking, and alkylation 
- Topoisomerase (I and II) 
and helicase inhibition 
- Inhibition of protein  and DNA 
synthesis  
- Interference with DNA unwinding 
and separation 
- Onset of cell dysfunction or death 
ROS production 
- Quinone-semi-quinone 
recycling 
- DOX-iron recycling 
- DNA damage 
- Lipid peroxidation 
- Increased DNA alkylation 
- cell death induction via caspases 
Damage to cell 
membranes 
- Plasma protein binding 
- Production of free radicals and  
disruption of lipid bilayer  
 
1.6.1 Doxorubicin-induced cardiotoxicity 
Cardiotoxicity, as defined by the National Cancer Institute (2017), is toxicity that affects the 
ability of the heart to do fulfil its function. This term however is rather ambiguous considering 
that numerous drugs and other chemotherapeutics adversely affect the heart and its vasculature. 
DOX-induced cardiotoxicity is hypothesized to arise from multiple pathways including 
oxidative stress (Octavia et al., 2012), apoptosis (Arola et al., 2000), disruption of iron 
(Gammella et al., 2014) and calcium homeostasis (Chen et al., 2007). As well as mitochondrial 
dysfunction (Zhang et al., 2009), inhibition of nucleic acid and protein (Takemura & Fujiwara, 
2007), and changes in the adrenergic function (Ferreira et al., 2008; Carvalho, 2013) as 
demonstrated in Table 1.3. Since the degree of myocardial damage induced by DOX therapy 
varies depending on dose, duration and DOX formulation, cardiotoxicity that induces 
myocardial dysfunction is known as acute, while cardiotoxicity associated with myocardial cell 
death is classified as chronic. 
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Table 1.3: Different mechanisms by which DOX induces cardiotoxicity  
(adopted from Carvalho et al., 2013; Damiani et al., 2016)  
Cardiotoxic Mechanisms Pathways effected Outcomes 
ROS generation 
- Enzymatically via the mitochondrial 
respiratory chain, or non-
enzymatically via DOX-iron 
complexes 
- Increased free radical 
production, iron 
accumulation and oxidative 
damage 
Mitochondrial dysfunction 
- Disruption of mitochondrial 
dynamics (fusion and fission) 
- Cell death, oxidative 
stress and calcium 
dysregulation 
Topoismerase and 
helicase inhibition 
- DOX binds to DNA and to enzymes 
involved in DNA healing  
- Inhibits DNA replication, 
leading to activation cell 
death pathways 
Damage membrane 
phospholipids  
(e.g.: cardiolipin) 
- Drug-lipid complex formation  
- Disruption of oxidative 
phosphorylation 
Cell death induction 
- Caspase dependent and 
independent pathways of apoptosis 
- Death of cardiomyocytes 
 
1.6.2 Cardiotoxicity classification 
Acute or early-onset cardiotoxicity occurs either during or shortly after treatment. Although 
this is clinically manageable, it results in mild to moderate irregularities in heart beat 
functionality (Carvalho et al., 2013; Zhang et al., 2012). Also included in this classification is 
sub-acute cardiotoxicity which can occur a few weeks after treatment. It is characterized by the 
oedema and inflammation of the pericardial and myocardial walls (pericarditis–myocarditis 
syndrome) (Barrett-Lee et al., 2009; Thorn, et al., 2012). In contrast to acute toxicity, chronic 
cardiotoxicity occurs weeks, months (early-onset), years and even decades (late-onset) 
following chemotherapy (Figure 1.5). Not only is this type of cardiotoxicity the most 
detrimental due to its dose-dependent effects, it is associated with numerous risk factors and 
has no cure. Clinically it is characterized by a decline in blood pressure and ejection fraction, 
along an increased heart rate with failure (Barrett-Lee et al., 2009; Zhang et al., 2012; Thorn et 
al., 2012). While these long term effects may have been mainly attributed to oxidative stress 
and consequently apoptosis downstream, clinical data obtained from anti-oxidant therapy has 
produced disappointing results (Vincent et al., 2013). As mitochondria are responsible for ROS 
production in a cell and they are also a target of DOX damage, attention has since shifted from 
oxidative stress to mitochondrial dysfunction as a major contributor to cardiotoxicity (Cove-
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Smith et al., 2014). Mitochondrial dysfunction has been discussed in this review (sub-section 
1.1.3) albeit in the context of obesity, however this phenomenon has been implicated to play an 
important role in this scenario as these organelles are the earliest and most prominent histo-
morphological features of DOX-induced cardiomyopathy (Minotti et al., 1999). It is has been 
demonstrated that DOX has a high affinity for cardiolipin, a phospholipid enriched in the inner 
mitochondrial membrane, which results in the accumulation of DOX within mitochondria. This 
accumulation drives the sustained free radical production and oxidative damage (Li et al., 2010) 
The end result of these events is mitochondrial dysfunction due to an imbalance in the fusion 
and fission processes. Even though the relationship between acute and chronic cardiotoxicity 
has not been well illustrated to establish whether the two conditions are directly, partially or 
independently connected, they are currently seen as two unique conditions despite sharing 
similar risk factors. 
 
Figure 1.5: Classification of DOX-induced cardiotoxicity 
 
1.6.3 Risk factors associated with the development of cardiotoxicity 
There are various risk factors that contribute to an individual developing DOX-induced 
cardiotoxicity as illustrated in Figure 1.6. These include age, gender, previous chemotherapy 
use, cumulative DOX dose, an underlying heart condition and any other inflammatory condition 
that endangers the heart such as obesity and insulin resistance (Pai & Nahata, 2000). As obesity 
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is the most critical risk factor associated with CVD (section 1.3), cancer (section 1.4) and now 
DOX-induced cardiotoxicity, there are clear overlaps in mechanisms and signalling pathways 
involved, all of which have already been elaborated on previously in this review. Work 
published by Barrett-Lee and collegues (2009) demonstrated an increased risk of heart failure 
with an increase in DOX cumulative dose. Furthermore, young people below the age of 15 and 
the older generation (older than 60 years) were found to be at most risk. In fact, similar work 
published in the 1970s showed a 3% risk of cardiotoxicity at cumulative DOX doses of 400 
mg/m², 7% at 550 mg/m² and 18% at 700 mg/m² (Vonn Hoff et al., 1979). Through this work 
and the work of many others, DOX cumulative doses are now limited to 400 mg/m². It is well 
known that women are at less risk of CVD or maintain a better cardiac function than men at 
least before menopause, due to their hormonal status (Regitz-Zagrosek et al., 2006). However, 
in this context, sexual dimorphism has been understudied. From what is known from pre-
clinical models, DOX-induced toxicity in males is associated with severe weight loss, reduced 
survival rates, changes in myocardial function and mitochondrial respiration, a down-regulation 
in signalling pathways responsible for energy production and decreased mitochondrial 
biogenesis, cardiolipin content and mitochondrial DNA (Moulin et al., 2015). While the exact 
mechanisms mediating these sexual differences in unknown, further research aimed at 
exploring the role of sex hormones is necessary. 
 
 
Figure 1.6: Risk factors associated with the development of DOX-induced cardiotoxicity 
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In conclusion, this review has attempted to provide a brief synopsis of the complications that 
arise during obesity. Not only does this disease risk myocardial health and performance, is it a 
risk factor for other inflammatory associated diseases that also place the heart at risk. 
Considering that these diseases have mainly been studied in isolation, there are very few, if any 
studies that have investigated cancer and cardiotoxicity in the context of obesity, to better 
understand the complex relationship that these diseases have with one another and how 
cardiovascular function is adversely affected in this co-morbid state. Therefore, this study 
hypothesizes that cancer in an obese environment increases the risk of developing early-stage 
DOX-induced cardiotoxicity. We aim to establish a relatable diet-induced obese mouse model 
that will be inoculated with breast cancer cells to induce tumours, and then further treated with 
DOX. To evaluate the effects of obesity, cancer and DOX treatment on the heart, markers of 
inflammation, oxidative stress, cell death, fibrosis and adipokines concentrations will thus be 
analysed.  
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2.  MATERIALS AND METHODS 
2.1  Ethical considerations  
All in vivo experiments were ethically approved (ethics no# SU-ACUM13-00015) and 
performed under conditions that complied with the guidelines for the care and use of laboratory 
animals implemented at Stellenbosch University. Experiments conforms to the accepted 
standards for the use of animals in research and teaching as reflected in the South African 
National Standards 10386: 2008 (Appendix F).  
2.2 Study design 
The in vivo study employed the use of female C57BL6 mice, which were weaned at 3 weeks of 
age and allowed to acclimatize for one week before the study commenced. Mice were housed 
in groups of five in static micro-isolation cages following a 12-hour dark/light cycle in a 
pathogen-free environment. Room temperature was maintained at ± 22 ºC. Standard mice chow 
and water was available ad libitum, and the general welfare of the animals was monitored daily. 
This study investigated DOX induced cardiotoxicity in an obese tumour bearing mice model. 
In brief, the mice were divided into two groups where one group was fed a high fed diet to 
induce obesity and the other a standard diet. Following obesity, the two groups were divided 
and half of the obese and standard mice were inoculated with tumours. The four remaining 
groups were further divided into eight experimental groups where half were subjected to DOX 
treatment. Figure 2.1 details the different experimental groups. A detailed discussion of the 
study design follows below. 
2.2.1 Obesity Induction and Diet Composition 
Following the acclimatization period, mice were randomly divided into two experimental 
groups and were fed either a standard diet (D12450J, Research diet Inc., New Jersey, USA) or 
a high fat diet (D12492 Research diet Inc., New Jersey, USA) as outlined in Table 2.1. The 
high fat diet was used to induce obesity, and is specially designed such that the standard diet 
matches the sucrose components of the high fat diet. In addition, the standard diet was employed 
instead of the standard laboratory chow diet to prevent the potential effects of phytoestrogens, 
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which have previously been shown to produce variation in standard chow weight gain (Ulman, 
2011). The animals remained on their respective diets throughout the duration of the study. 
Table 2.1: Dietary components of the standard and high fat diets 
(Adopted from Ulman, 2011)  
Diet component 
                          
Standard diet (D12450J) High fat diet (D12492) 
gram % kcal% gram % kcal% 
Protein 19.2 20 26.2 20 
Carbohydrates  67.3 70 26.3 20 
Fat  4.3 10 34.9 60 
Total   100  100 
Kcal/gram 3.85  5.24  
Ingredients gram Kcal gram Kcal 
Casein, 30 Mesh 200 200 800 200 800 
L-Cystine 3 12 3 12 
Corn Starch 506.2 2024.8 0 0 
Maltodextrin 10 125 500 125 500 
Sucrose 68.8 275.2 68.8 275.2 
Cellulose BW200 50 0 50 0 
Soybean Oil 25 225 25 225 
Lard* 20 180 245 2205 
Mineral Mix S10026 10 0 10 0 
Dicalcium Phosphate 13 0 13 0 
Calcium Carbonate 5.5 0 5.5 0 
Potassium Citrate, 1 H2O 6.5 0 6.5 0 
Vitamin Mix V10001 10 40 10 40 
Choline Bitartrate 2 0 2 0 
FD&C Yellow Dye #5 0.04 0 - - 
FD&C Blue Dye #1 0.01 0 0.05 0 
Total 1055.05 4057 773.85 4057 
Cholesterol (mg)/4057 kcal 
 
54.4 
 
216.4 
Cholesterol (mg)/kg 
 
51.6 
 
279.6 
 
2.2.2 Cancer cell inoculation and tumour growth  
After eight weeks on the different diets, animals were further divided into two more groups, 
where half of the animals on the standard and  high fat diet were inoculated with cancer cells. 
E0771 cells were grown and maintained as described in Appendix B. The cells were prepared 
for each mouse and mice were restrained and anaesthetized under 3% (v/v) isoflurane (Isofor, 
Safeline Pharmaceuticals, Florida, South Africa) in an anaesthetic chamber. The fourth 
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mammary pad was then subcutaneously inoculated with ~1.2 x 105 E0771 breast cancer cells. 
The tumour size was monitored using digital callipers by taking three measurements: 
perpendicular, horizontal and diagonal to the mouse’s body. The volume of the tumours was 
calculated as follows: from the three readings taken, the largest volume served as the length 
(longitudinal/perpendicular) and the smallest volume served as the width 
(transverse/horizontal). The following formula was used:  
Tumour volume (mm3) = 0.5 x (length x width2) 
Once tumours reached a volume of ± 200-300 mm3, chemotherapeutic drug treatment 
commenced. 
2.2.3 Doxorubicin preparation and administration 
DOX (D5794, LKT® laboratories, Minnesota, USA) stock solution was prepared as described 
in Appendix C. Mice were weighed prior to drug administration in order to determine the 
volume of drug. Following this, the above four groups were again randomly divided to create 
eight experimental groups. Where half of the animals on the standard diet, standard diet with 
tumour, high fat diet and the high fat diet with tumours received DOX treatment. DOX was 
administered via intraperitoneal injection every fourth day at a concentration of 4 mg/kg, 
resulting in a cumulative dose of 12 mg/kg. The vehicle control group received three 
intraperitoneal injections of Hank’s balanced salt solution –HBSS (H8264, Sigma-Aldrich, 
Missouri, USA). Four days after the last injection, mice were euthanized following complete 
sedation with 3% (v/v) isoflurane (Isofor, Safeline Pharmaceuticals, Florida, South Africa) and 
cervical dislocation was performed to confirm death. Subsequently, blood was collected and 
hearts were rapidly excised where half of the tissue was frozen in liquid nitrogen  for molecular 
analysis and the other preserved in formalin for histology. Additional gonadal adipose tissue 
(located in the third and fourth quadrant of mouse) was weighted and used to calculate gonadal 
adiposity as percentage of final body weight. A summary of the study design and experimental 
groups is demonstrated in Figure 2.1 below. 
2.2.4 Humane endpoints  
As this study involves the inoculation of tumour cells, as well as chemotherapy administration, 
the following humane endpoints were established:  
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 When tumour growth restricted mobility of the mice or influenced general welfare 
 When the mice began to bite tumours 
 When the mice exhibited changes in posture and facial expression, as determined using the 
grimace scale (see Appendix E) 
Figure 2.1: Study Design 
2.3 Blood analysis 
The following experimental analysis was performed with the assistance of a specialized 
technician from the LUMINEX PLATFORM at the Division of Molecular Biology and Human 
Genetics, Stellenbosch University Medical Campus. 
2.3.1  Luminex multiplex assay 
After blood was collected it was separated into plasma using EDTA tubes (VGRV450474R, 
Lasec, Cape Town, South Africa). The plasma was used to test for various analytes using the 
ProcartaPlex Mix & Match Mouse 4-plex Luminex kit (PPX-04-MXCE327, Biocom-
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Invitrogen, Massachusetts, USA) custom panel. The following four analytes were measured 
simultaneously using the Bio-Plex® MAGPIX™ Multiplex reader (MAGPIX13046704, Bio-
Rad Laboratories, Inc., California, USA): TNF-α (EX01-20607-901), IL-6 (EX01A-20603-
901), IL-10 (EPX01A-20614-901) and Leptin (EX01A-12039-901). The assay utilises 
fluorescent dyes and magnetic bead-based Luminex XMAP® technology. Each analysis was 
assigned different microspheres (beads) that are internally colour coded with florescent dyes 
and coated with a capture antibody specific for the analyte. The plasma was pooled together 
with the capture beads and incubated for one hour. The biotinylated detection antibody was 
added and incubated for 30 minutes to form an immune complex and then washed. 
Quantification was performed by the detection of the reporter molecule Streptavidin-
Phycoerythrin conjugate, which was added to bind to the detection antibody as each analyte 
fluoresces at a different signal. Data obtained was expressed in pg/ml for each analyte. 
 In addition, fasting blood glucose, triglyceride and lactate levels were taken using the tail prick 
method where 5 µl of blood was collected on test strips using the Accu-Chek ® Performa Nano 
(Roche Diagnostics, Mannheim, Germany) and Accutrend Plus® (Roche Diagnostics, 
Mannheim, Germany) respectively.  
2.4 Oxidative stress analysis  
The following experimental analysis were performed at the Oxidative Stress Centre at Cape 
Peninsula University of Technology (CPUT). 
2.4.1 Measurement of early stage lipid peroxidation (Conjugated Dienes assay) 
Conjugated dienes (CDs) are polyunsaturated free fatty acids and serves as an early marker of 
lipid peroxidation. This assay makes use of UV light using a Multiskan™ Spectrophotometer 
(51119200, Thermo Electron Corporation, Massachusetts, USA). A volume of  ± 50 µl of tissue 
lysate was prepared in phosphate buffer and added to a centrifuge tube in a 1:5 ratio with 250 
µl chloroform-methanol buffer (see Appendix C). The Eppendorf tubes were centrifuged at 14 
000 rpm for 1 minute, where after two layers were formed and 200 µl of the bottom chloroform 
layer was transferred to a new tube. Tubes were left overnight in 4°C with the lids open to allow 
for evaporation under a flow of nitrogen. The following day, 1 ml cyclohexane (102822, Merck, 
Massachusetts, USA) was added to each tube, which was then vortexed for ± 20 seconds. A 
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volume of 300 µl of the blank (cyclohexane) and tissue lysate samples were loaded in triplicate 
into clear UV 96 wells plates. The plate was read at a wavelength of 220-320 nm to determine 
absorbance at 234 nm. The content of CDs was then expressed as Abs234/gram wet weight of 
the myocardial tissue. 
2.4.2 Measurement of late stage lipid peroxidation (TBARS assay) 
Malondialdehyde (MDA) is a by-product of lipid peroxidation and a late marker for oxidative 
stress. The thiobarbituric acid reactive substance (TBARS) assay was used to measure the 
concentration of MDA’s within the tissue lysate. MDA interacts with thiobarbituric acid (TBA) 
to form a single MDA-TBA adduct, which can be measured colourimetrically as it produces a 
pink colour (Noeman et al., 2011). This reaction is used proportionally to quantitatively 
measure the by-products produced (Devasagayam et al., 2004). Tissue samples were prepared 
in a phosphate buffer (see Appendix B & C) in 1:10 ratio and homogenised using 
POLYTRON® PT 2100 Homogenizer (Thermo Fisher Scientific, Massachusetts, USA). The 
supernatant was collected and a volume of 50 µl supernatant was added to 6.25 µl TBA reagent 
to create an acidic environment and then incubated for 45 minutes in a 90 °C water bath. After 
cooling, the supernatant was then transferred to a 96-well flat bottom plate and the absorbance 
was measured at 532 nm using a Multiskan ™Spectrophotometer (Thermo Electron 
Corporation, 51119200, Massachusetts, USA). The absorbance reading obtained is directly 
proportional to amount of MDA present in the tissue lysate. The concentration of MDA per 
sample was determined using the MDA (820756, Merck, Massachusetts, USA) equivalence 
standard and expressed as µmol/gram of MDA. 
2.5 Western blot analysis 
2.5.1 Tissue lysate preparation 
To extract and isolate protein, ± 20 mg of heart tissue was incubated in 200 µl (1:10 ratio) of 
Radio-immunoprecipitation buffer (RIPA) (see Appendix C). The tissues were homogenized 
on ice using POLYTRON® PT 2100 Homogenizer (Thermo Fisher Scientific , Massachusetts, 
USA) and then sonicated using an Ultrasonic Liquid processor (630-0427, Sonics & Material 
Inc., Newton, USA) for 15 seconds at 10 Amps. Once the foam had settled the lysates were 
centrifuged at 12 000 rpm for 15 seconds at 4 °C. The pellet was discarded, and the supernatant 
was transferred to a pre-chilled Eppendorf tube. 
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2.5.2 Protein determination 
Protein concentration was determined using the Direct Detect™ Infrared Spectrometer 
(DDHW00010,Merck, Massachusetts, USA), which uses infrared rays (IR) to detect peptide 
bonds which make up the protein chain. Briefly, a 2 µl of each tissue lysate sample was placed 
on the hydrophilic polytetrafluoroethylene (PTFE) transparent membrane and then air-dried 
prior to the quantification of protein in mg/ml. In accordance with the manufactures 
instructions, RIPA buffer was used as a blank. 
2.5.3 Preparation of tissue lysates, protein separation and transfer 
Samples containing ~40 mg protein content were prepared on ice for western blotting. A 
volume of 15 µl of Laemmli’s buffer was added and then boiled for 5 minutes at 95 ºC. Samples 
were centrifuged at 10 000 rpm for 1 minute at room temperature before separation by 
electrophoresis. See Appendix C for detailed buffer protocols.  
Using the Mini- PROTEAN® II electrophoresis cell (165-2940, Bio-Rad, California, USA) 
proteins were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE). The samples were loaded into the gel with a commercial molecular weight marker, 
BluEye Prestained ladder (PM007-0500, Biocom Biotech, Centurion, SA) Proteins were 
separated by electrophoresis on a 12% TGX stain free™ FastCast™ acrylamide gel (1610185, 
Bio-Rad Laboratories, Inc. California, USA) at a constant voltage of 100 V and current of 300 
mA for approximately 60-90 minutes (see Appendix B). Once the proteins had separated, the 
gel was removed and then activated using the ChemiDoc™ XRS + System (170-8265, Bio-Rad 
Laboratories, Inc., California, USA). After gel activation, the resolved proteins were transferred 
to polyvinylidene fluoride (PVDF) membranes using the Trans-Blot® Turbo™ RTA Mini PVDF 
Transfer Kit (1704270, Bio-Rad Laboratories, Inc., California, USA). Transfer stacks were 
activated in transfer buffer for 3 minutes. The PVDF membrane was activated in 100% 
methanol (1.06007, Merck, Massachusetts, USA) until translucent and then placed in transfer 
buffer for 3 minutes.  The transfer stack was assembled as depicted in Figure 2.2. 
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Figure 2.2: Transfer stack preparation layout 
The ‘sandwich’ was prepared as follows: ①Cassette  ②blotting paper  ③PVDF 
membrane ④Gel ⑤blotting paper⑥Cassette (Image from protocol of Bio-Rad 
Laboratories, Inc., California, USA) 
The proteins from the gel were transferred to the membrane for 30 minutes at 25 V, 1.0 A using 
the Trans-Blot® Turbo™ transfer system (1704270, Bio-Rad Laboratories, Inc., Calornia, USA). 
After transfer, membranes were soaked for 30 seconds in 100% methanol (1.06007, Merck, 
Massachusetts, USA, and protein transfer was confirmed using the ChemiDoc™ XRS+ System. 
The membranes were washed in 1x Tris-buffer saline-TWEEN 20 (TBS-T, see Appendix C) 
and incubated in blocking buffer containing 5% (v/v) fat free milk in 1x TBS-T for two hours 
at room temperature to prevent non-specific binding. After blocking, the membranes were 
washed in 1x TBS-T (3x for 5 minutes) and then placed in 5 ml TBS-T containing specific 
primary antibody overnight or 48 hours at 4ºC shown in  Table 2.2. The membranes were 
washed in 1x TBS-T (3x for 5 minutes) and incubated in horseradish peroxidase-conjugated 
secondary antibody for one hour at room temperature. 
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Table 2.2: Primary and secondary antibodies used for western blot analysis 
 
Primary 
Antibody 
Molecular weight 
(kDa) 
Secondary  
Antibody 
Dilution  
factor 
Company  
and Catalogue # 
Caspase-3 
Total: 35 kDa 
Cleaved: 17& 19 kDa 
Anti-Rabbit 1:1000 
Cell Signalling Technology  
#9662S 
PARP1 
Total:116 kDa 
Cleaved: 89 kDa 
Anti-Rabbit 1:1000 
Cell Signalling Technology  
#9532S 
Secondary Antibody 
Anti-Rabbit Secondary HRP-Linked 1:10000 
Cell Signalling Technology  
#7074S 
 
2.5.4 Visualisation 
After removing membranes from the secondary antibody, membranes were washed in  1x TBS-
T (3x for 5 minutes) and then covered with Clarity™ ECL Western Blotting Substrate 
(1705061, Bio-Rad Laboratories Inc., California, USA) and exposed to UV light using the 
ChemiDoc™ XRS+ System to quantify the expression of the specific protein bands. 
2.5.5 Total protein standardizing 
A modern method using Image Lab ™ Software (Bio-Rad Laboratories Inc., California, USA), 
and the total protein image of the membrane was used to standardize protein expression to 
account for equal protein loading. 
2.6 Histological analysis 
2.6.1 Tissue processing  
For histological analysis, the 10% neutral formalin-fixed heart tissue was placed in a pre-
labelled embedding cassette. The tissue was then processed using the Shandon Elliot Suplex 
processor (SCE 0540, Biotech laboratories, UK) using  a 20-hour processing protocol outlined 
as follows: 1) dehydration in different concentrations of alcohol, 2) clearing tissue with xylene, 
and 3) impregnation of tissue with Paraplast® wax (327204, Sigma Aldrich, Missouri, USA), 
(See Appendix B, for full procedure). Upon completion, the tissue was embedded into a block 
in Paraplast® wax at 60ºC using the Leica Modular Tissue Embedder (EG1160, Leica 
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Biosystems, Wetzlar, Germany) and then sectioned into 5 µm sections with a Leica microtome 
(RM2125 RTS, Leica Biosystems, Wetzlar, Germany). The ribbons of tissue were placed onto 
a warm water bath to stretch out the tissue before mounting it onto a glass slide; the slides were 
then placed in a 70ºC oven prior to specific histological staining. 
2.7 Histological staining  
The following experimental analysis was performed under the supervision and assistance of 
histological technician, at the Stellenbosch University medical campus, histological lab. 
2.7.1 Haematoxylin and Eosin staining  
The standard Haematoxylin and Eosin (H&E) staining method allows for the visualization of 
general morphology. H&E are two different dyes: haematoxylin being basic, stains acidic 
components of a cell, while eosin is acidic, and stains basic cellular components. The nucleus 
of the cell is stained blue by haematoxylin and the cytoplasm is stained pink by eosin. Prior to 
staining, the slides were placed in an incubator for the wax to melt off the tissue. Heart tissue 
sections, as outlined in section 2.6.1, were stained with H&E using the Leica AutoStainer XL 
(ST5010, Leica Biosystems, Wetzlar, Germany) following the procedure in Table 2.3. The 
haematoxylin solution (SAAR28001LC, Merck, Massachusetts, USA) and eosin solution 
(3801600E, Leica Biosystems, Wetzlar, Germany) was filtered before the run. Once staining 
was complete, the tissue was covered with a glass cover slip and DPX mounting medium 
(06522, Sigma-Alrich, Missouri, USA) was used to cover the heart tissue sections and left to 
dry for 48 hours. 
Slides were analysed by 40x objective lens on the Nikon Eclipse E400 microscope (Nikon 
instruments, Tokyo, Japan) with a SPOT RT Color Digital camera (Diagnostics Instruments, 
Inc., Michigan, USA) with NIS Elements software. Images were analysed by using scoring 
system to quantify damage based on study by Selçuk and colleagues (2015).  
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Table 2.3: H&E staining procedure 
 
Step Solution  Time  Repetitions  
1  Oven (60˚C)  2 minutes  X1  
2  Xylene  5 minutes   X2  
3  Ethanol (99%)  2 minutes  X2  
4  Ethanol (96%)  2 minutes   X1  
5  Ethanol (70%)  2 minutes  X1  
6  Tap water  2 minutes   X1  
7  Haematoxylin  8 minutes  X1  
8  Running water  5 minutes  X1  
9  Eosin  4 minutes  X1  
10  Running water  1 minutes  X1  
11  Ethanol (70%)  30 seconds  X1  
12  Ethanol (96%)  30 seconds  X1  
13  Ethanol (99%)  30 seconds  X1  
14  Xylene  1 minutes   X1  
 
2.7.2 Sirius Red stain for collagen 
Sirius red stain is specific application to colourimetrically stain collagen (Horobin et al., 2002). 
Prior to staining slides are placed in an incubator for the wax to melt off the tissue. The 
haematoxylin (SAAR28001LC, Merck, Massachusetts, USA) and Picrosirius red solutions was 
filtered before use (see appendix C for full protocol). Table 2.4 describes the staining procedure 
of Picrosirius red staining procedure that was followed. Once staining was complete, tissue was 
covered with a glass cover slip, DPX mounting medium and left to dry for 48 hours. 
Slides were analysed using the same microscope settings as mention in section 2.7.1. Images 
were analysed by using Image J software by colour threshold method which is explained in 
detail in Appendix A. 
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Table 2.4: Procedure of Picrosirius Red staining 
 
Step Solution Time Repetitions 
1  Oven (60˚C) 2 minutes  X1  
2  Xylene 5 minutes   X2  
3  Ethanol (99%) 2 minutes  X2  
4  Ethanol (96%) 2 minutes  X1  
5  Ethanol (70%) 2 minutes   X1  
6  Tap water 1 minutes   X1  
7  Haematoxylin 8 minutes  X1  
8  Running water  10 minutes  X1  
9  Picrosirius red 1 hour X1 
10  Acidified water  30 seconds X2 
11   Physically remove water from sides by vigorously shaking to air-dry water. 
12  Ethanol (70%)  30-seconds X1 
13 Ethanol (96%)  30 seconds X2 
14 Ethanol (99%)  30 seconds X1 
15 Xylene 1 minute X1 
 
2.8 Statistical analysis 
MS Excel was used to capture the data and data analysis software system, Graph Pad Software 
version 7 (San Diego California, USA) was used to do statistical analysis and to generate 
graphs. To compare two groups, an unpaired t-test was performed. For more than two groups, 
a one-way ANOVA or were applicable a two-way repeat measurement ANOVA with a 
Bonferroni post hoc test for both test was performed. Statistical significance was defined by 
p<0.05. 
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3. RESULTS 
3.1 Establishing diet-induced obesity 
A basic criteria used for both animals and humans to assess the development of obesity is to 
evaluate overall body weight gain as well as the increase fat content in the body (Hariri & 
Thibault, 2010). Although in humans BMI is used as a method to define and classify obesity, 
the increased body weight of rodents is confirmed by significantly higher body weight 
percentages. This study utilized a high fat diet (HFD) to induce obesity and this was matched 
calorie wise with a standard diet (SD) which served as the control group. 
3.1.1 Body weight  
No differences in initial body weight was observed before the introduction of the respective 
diets (Figures 3.1 & 3.2A). After five weeks however, mice fed the HFD showed a significant 
increase in body weight when compared to mice fed the SD. At the end of the treatment 
protocol, the final body weight for the HFD group was 29.24 ± 1.99 g, (p<0.0001) when 
compared to the SD group (19.72 ± 0.52 g) (Figures 3.1 & 3.2B). This equates to a more than 
two-fold increase in percentage body weight change between the groups (HFD: 90.72 ± 
11.08%, p<0.001 versus SD: 34.69 ± 7.13%) (Figure 3.2C). To further confirm obesity, 
adiposity was considerably elevated in the HFD group (4.68 ± 0.70%, p<0.001) than the SD 
group (1.37 ± 0.16%) (Figure 3.2D). According to these results, it is clear that the chosen high 
fat diet used in this study was sufficient to induce obesity. 
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Figure 3.1: Percent body weight gain overtime of mice fed a standard diet (S) or high fat 
diet (H) for ±12 weeks. Body weight data was recorded twice a week from the start of the 
respective diets until the end of the treatment protocol. Data is represented as mean + SEM 
(n=8-10). *p<0.05, **p<0.01, ***p<0.001 versus S.  
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Figure 3.2: Biometric parameters of mice fed a standard (S) or high fat diet for ±12 
weeks. (A) Initial body weight, (B) final body weight before euthanasia, (C) percentage (%) 
body weight gain and (D) percentage (%) gonadal adiposity of experimental groups. Data is 
represented as mean ± SEM (n=8-10). ***p<0.001 versus S. Abbreviations: g – grams 
 
3.1.2  Food consumption and fluid intake 
To complement the body weight data above, the total amount of food (Figure 3.3) and water 
(Figure 3.4) consumed was determined for each group on a weekly basis. As expected, mice 
fed the high fat diet consumed more rat chow than those on the standard diet. Significance was 
mainly observed after weeks 1, 4, 10 and 12. Additionally, these animals also consumed more 
water although statistically these results were not significant. 
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Figure 3.3: Weekly food consumption in mice fed a standard (S) or high fat diet (H) for 
±12 weeks. Food intake was measured weekly for each group to determine the average 
kilocalories (kcal) consumed. Data is represented as mean + SEM (n=8-10). *p<0.05, **p<0.01 
versus SD. Abbreviations: kilocal – kilocalories. 
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Figure 3.4: Weekly water consumption in mice fed a standard (S) or high fat diet (H) for 
±12 weeks. Water intake was measured daily but evaluated weekly for each group to 
determine the average amount of water consumed. Data is represented as mean + SEM (n=8-
10). Abbreviations: ml – millilitres. 
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3.1.3  Fasting blood parameters 
Prior to euthanasia, mice were fasted for 12 hours where fasting blood glucose (Figure 3.5A), 
triglycerides (Figure 3.5B) and lactate (Figure 3.5C) levels could be determined. Moreover, 
adipokines such as TNF-α (Figure 3.5D), IL-6 (Figure 3.5E) and leptin (Figure 3.5F) were also 
evaluated. While no noteworthy changes were observed for triglycerides, lactate, TNF-α and 
IL-6 levels, fasting blood glucose and leptin levels were significantly up-regulated in the HFD 
group (glucose: 8.50 ± 0.40 mmol/L, p<0.01; leptin: 11671.00 ± 4538.00 pg/ml, p<0.05) versus 
the SD group (glucose: 6.00 ± 0.50 mmol/L; leptin: 1072.00 ± 403.40 pg/ml). Although insulin 
levels were not measured in this study so that the homeostatic model assessment of insulin 
resistance (HOMA-IR) could also be determined, the elevated fasting glucose levels in this 
group is possibly indicative of insulin resistance. The increased leptin levels observed further 
confirm the state of obesity. 
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Figure 3.5: Fasting blood parameters of mice fed a standard (S) or high fat diet (H) for 
±12 weeks. Mice were starved for 12 hours prior to euthanasia to determine (A) glucose, (B) 
triglycerides, (C) lactate, (D) TNF-α, (E) interleukin-6 and (F) leptin levels. Data is represented 
as mean ± SEM (n=5-6). **p<0.01, *p<0.05 versus S.  
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3.2  Effect of obesity on the heart  
The mechanisms by which obesity affects the heart is complex due to the various changes that 
take place. Our next objective was then to evaluate the impact of diet-induced obesity on 
myocardial health. 
3.2.1 The impact of diet-induced obesity on the cardiac hypertrophy index  
Cardiac hypertrophy is known as the increased growth of the heart associated with thickening 
of the ventricular walls. On the one hand, physiological cardiac hypertrophy is associated with 
the increased size of the heart to compensate for increased functionality during activities such 
as exercise. ‘Athletes heart’ as it is commonly known, results in hyperplasia to increase the 
output rate of blood supply, however the cardiac morphology remains the same. On the other 
hand, pathological cardiac hypertrophy, increases the size of the heart as a result of disease. 
Often when cardiomyocytes die, fibroblasts invade cardiac tissue to deposit collagen to replace 
dead cardiomyocytes, resulting in fibrosis (Kavazis, 2015). For this study, the heart to final 
body weight ratio was used to examine hypertrophy as a result of the HFD. We have already 
established that the HFD increased body weight (Figure 3.2B); however, no changes were 
observed in overall final heart weight (Figure 3.6A). Interestingly, the heart-to-body weight 
ratio revealed a surprising a result. Mice on the HFD demonstrated a significantly reduced ratio 
(0.004 ± 0.0002, p<0.001) than those in the SD group (0.006 ± 0.0002) (Figure 3.6B). While 
this result does not definitively demonstrate pathological cardiac hypertrophy, it may indicate 
that by the time this study was terminated, it was too early for hypertrophy to be evident, 
therefore this is indicative that hypertrophy did not occur within the HFD group. 
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Figure 3.6: Cardiac hypertrophy index of mice fed a standard (S) or high fat diet (H) for 
±12 weeks. (A) Heart weight and (B) heart-to-body weight ratio of experimental groups. Data 
is represented as mean ± SEM (n=8-10). ***p<0.001 versus S. Abbreviations: g – grams, AU-
arbitrary units. 
 
3.2.2 The effect of a high fat diet on myocardial ultrastructure and collagen deposition 
To further evaluate potential changes in myocardial structure and the presence of fibrosis 
(Figure 3.7), H&E and Picrosiruis red stains (Figure 3.8) were performed respectively. A 
scoring system based on previously published data (Selçuk et al., 2015) was used to semi-
qualitatively assess heart tissue sections for various factors indicative of structural damage. 
According to the three parameters evaluated which included (i) eosinophilic cytoplasm and 
pyknotic nuclei indicating nuclear condensation, (ii) intra-cytoplamic vacuoles and (iii) 
inflammatory cell infiltration and congestion, no significant changes were observed for any of 
these parameters between the two groups. Using Image J analysis software, percentage fibrosis 
was determined. Although blood vessels contain connective tissue, they were specifically 
excluded when these sections were quantified. As shown in Figure 3.9, the percentage fibrosis 
in the HFD group was substantially reduced (1.17 ± 1.11%, p<0.001) when compared to the 
SD group (2.06 ± 1.65%).  
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Figure 3.7: H&E histological stains of heart tissue sections from mice fed a standard (S) 
or high fat diet (H) for ±12 weeks. Representative images of 5 µm thick heart sections picked 
at random and stained for structural defects. 4-5 images from three different mice per group 
were assessed. Magnification and scale bar: 10x and 100 µm (entire section) and 40x and 500 
µm (enlargement). Purple colour- nucleus and pink colour – cytoplasm.  
 
 
 
 
 
Figure 3.8: Picrosirius red histological stain of heart tissue sections from mice fed a 
standard (S) or high fat diet (H) for ±12 weeks. Representative images of 5 µm thick heart 
sections picked at random and stained for collagen deposition (fibrosis). 4-5 images from three 
different mice per group were assessed. Magnification and scale bar: 10x and 100 µm (entire 
section) and 40x and 500 µm (enlargement) Red colour – fibrosis (collagen I and II), yellow 
colour - cytoplasm, brown, grey or black colour- nucleus. 
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Figure 3.9: Percentage fibrosis in the myocardium of mice fed a standard (S) or high fat 
diet (H) for ±12 weeks. 4-5 images from three different mice per group were quantified for 
fibrosis using the colour threshold of Image J analysis software. Data is represented as mean 
± SEM (n=3). ***p<0.001 versus S.  
 
3.2.3 The effect of a high fat diet on apoptotic protein expression 
Caspase-3 is a 35 kDa protein that forms part of downstream processes responsible for cell 
death and contributes to the proteolytic cleavage of other proteins such as Poly (ADP-ribose) 
polymerase (PARP). The cleavage of both proteins is indicative of their activity status and the 
onset of apoptosis. However, the cleavage of PARP may not always be dependent on caspase-
3 activity. As shown in Figure 3.10 below, no statistically significant results were obtained 
between the two groups for the full length proteins detected. While this study also tried to detect 
the presence of the active forms of these proteins, we were unsuccessful. This could either imply 
that apoptosis is not taking place or that the cleaved products are degraded as soon as they are 
produced. 
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Figure 3.10: Relative apoptotic protein expression of mice fed a standard (S) or high fat 
diet (H) for ±12 weeks. Representative graphs and western blot images of full length caspase-
3 and PARP are illustrated. Protein expression was normalized to total protein and presented 
as a fold change relative to control (S). All values are presented as mean ± SEM (n=4). 
Abbreviations: AU - arbitrary units. 
 
3.2.4 The effect of a high fat diet on oxidative stress parameters  
It is widely accepted that oxidative stress is part and parcel of obesity, and is linked to other 
inflammatory conditions. Lipid peroxidation is oxidative stress damage to membrane 
phospholipids and thus forms part of the oxidative stress cascade. Conjugated diene (CD) 
production is an early biochemical event of lipid peroxidation, while malondialdehyde (MDA) 
is produced towards the end of the process. This study found a modest increase (0.177 ± 0.011 
µmol/g) and a modest decrease (0.003 ± 0.001 µmol/g) in CD and MDA levels respectively in 
the HFD group relative to the SD group, but these changes were insignificant (Figure 3.11). 
This lack of oxidative stress damage may also explain why no apoptotic activity was evident. 
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Figure 3.11: Oxidative stress parameters from mice fed a standard (S) or high fat diet 
(H) for ±12 weeks. Heart tissue lysates were used to evaluate the expression of early 
(conjugate dienes) and late (malondialdehydes) markers of lipid peroxidation. Data is 
represented as mean ± SEM (n=4-5). 
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3.3  Establishing a state of co-morbidity 
In order to establish a model of co-morbidity, this study randomly sub-divided the two main 
diet groups into a further two groups, where some groups where inoculated with cancer cells to 
induce tumors while others were not. By doing this, this study was simulating a condition of 
diet-induced obesity and cancer to create a co-morbid state, and how these inflammatory 
conditions affect cardiovascular health. 
3.3.1  Body weight  
Following the inoculation of cancerous cells at week eight, significant differences were 
observed between the groups fed a HFD (H) alone and a HFD plus tumour (H+T); as well as 
the SD plus tumour (S+T) and H+T groups (Figure 3.12). Considering that the HFD group lost 
weight and gonadal adiposity in the presence of a tumour (Figure 3.13B, C & D) when 
compared to the HFD group alone, these differences indicate that having cancer not only 
negatively influences body weight mass, the amount of fat accumulated in the body also 
decreases. However, being overweight or obese in this scenario appears to be protective, 
considering that the SD group lost considerable weight in the presence of a tumour by week 
nine. While losing weight as a result of obesity is beneficial, the loss of weight due to a disease 
in this context may prove to be detrimental.  
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Figure 3.12: Percent (%) body weight gain overtime of mice fed a standard diet (S) or 
high fat diet for ±12 weeks, and/or inoculated with cancer cells from eight weeks 
(represented by the vertical dotted line). Body weight data was recorded twice a week from the 
start of the respective diets and the inoculation of tumours until the end of the treatment 
protocol. Data is represented as mean ± SEM (n=8-10). *p<0.05 (S versus S+T), ###p<0.001, 
####p<0.0001 (versus H), $ p<0.05, $$p<0.01 (versus S+T).  
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Figure 3.13: Biometric parameters of mice fed standard (S) or high fat diet (H) for ±12 
weeks, and/or inoculated with cancer cells from eight weeks. (A) Initial body weight, (B) 
final body weight before euthanasia, (C) percentage (%) body weight gain and (D) percentage 
(%) gonadal adiposity of experimental groups. Data is represented as mean ± SEM (n=8-10). 
##p<0.01, ###p<0.001 (versus H). Abbreviations: g – grams. 
 
3.3.2 Food consumption and water intake  
To complement the body weight data above, the total amount of food (Figure 3.14) and water 
(Figure 3.15) consumed was determined for each group on a weekly basis. As illustrated in the 
figures below, considerable differences were observed between groups S+T and H+T at weeks 
8, 9 and 10, however this significance was lost by the time the study was completed. 
Interestingly, animals fed the SD in the presence of a tumour drank significantly more water 
that those animals fed the SD alone. 
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Figure 3.14: Weekly food consumption in mice fed a standard (S) or high fat diet (H) for 
±12 weeks, and/or inoculated with cancer cells from eight weeks (represented by the 
vertical dotted line). Food intake was measured weekly for each group to determine the 
average kilocalories (kcal) consumed. Data is represented as mean + SEM (n=8-10). $p<0.05, 
$$$p<0.001 (versus S+T). Abbreviations: kcal – kilocalories. 
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Figure 3.15: Weekly water consumption in mice fed a standard (S) or high fat diet (H) for 
±12 weeks, and/or inoculated with cancer cells from eight weeks (represented by the 
vertical dotted line). Water intake was measured daily but evaluated weekly for each group to 
determine the average amount of water consumed. Data is represented as mean + SEM (n=8-
10). **p<0.01, ****p<0.0001 (versus S). Abbreviations: ml – millilitres. 
 
3.3.3 Fasting blood parameters 
In an effort to determine whether the presence of a tumour induces a change in fasting blood 
parameters in experimental animals fed either a SD or HFD, glucose (Figure 3.16A), 
triglycerides (Figure 3.16B), lactate (Figure 3.16C), TNF-α (Figure 3.16D), IL-6 (Figure 3.16E) 
and leptin (Figure 3.16F) were measured. No noteworthy changes were observed in any of the 
parameters measured except for IL-6. In this case, a significant difference was observed 
between group H+T (64.95±11.62 pg/ml, p<0.01) when compared to HFD group alone 
(24.17±5.59 pg/ml). The over expression of this cytokine thus signifies the role that 
inflammation plays in promoting tumour progression by potentially regulating all hallmarks of 
cancer and multiple signalling pathways. 
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Figure 3.16: Fasting blood parameters of mice fed a standard (S) or high fat diet (H) for 
±12 weeks, and/or inoculated with cancer cells from eight weeks. Mice were starved for 
12 hours prior to euthanasia to determine (A) glucose, (B) triglycerides, (C) lactate, (D) TNF-
α, (E) interleukin-6 and (F) leptin levels. Data is represented as mean ± SEM (n=5-6). ##p<0.01 
(versus H).  
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3.4 Effect of obesity and cancer on the heart  
Our next objective for this study was to evaluate the impact of diet-induced obesity and cancer 
on myocardial health. Considering that both these conditions have an inflammatory component, 
it is likely that the secreted cytokines can also influence the function of the heart. 
3.4.1 The impact of diet-induced obesity and cancer on the cardiac hypertrophy index  
According to the results obtained (Figure 3.17A), the overall heart weight was significantly 
reduced in both groups that had tumours (S+T: 0.09±0.004 g, p<0.05; H+T: 0.10±0.005 g, 
p<0.05) when compared to their control counterparts alone (S: 0.11±0.005 g; H: 0.13±0.005 g). 
However, taking into consideration the final body weight of all experimental animals, the heart-
to-body weight ratio did not show any significant changes in any of the groups, and thus 
indicates that no hypertrophy took place in this scenario. 
 
 
Figure 3.17: Cardiac hypertrophy index of mice fed a standard (S) or High fat diet (H) for 
±12 weeks, and/or inoculated with cancer cells from eight weeks. (A) Heart weight and 
(B) heart-to-body weight ratio of experimental groups. Data is represented as mean ± SEM 
(n=8-10). *p<0.05 (versus S), #p<0.05 (versus H). Abbreviations: g – grams, AU-arbitrary units. 
3.4.2 The effect of a high fat diet and cancer on myocardial ultrastructure and collagen 
deposition 
Although the physical measurement of the heart-to-body weight ratio is important to evaluate 
potential cardiac hypertrophy, histological analysis of the tissue specimens often provides a 
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better visual representation of potential damage within the heart that may have occurred with 
the different experimental groups. The same scoring system that was used in Section 3.2.2 was 
also utilised in the current section. While neither diet had a major impact on structural defects 
of the myocardium, the presence of a tumour in the SD group (S+T) induced interstitial 
congestion (indicated by asterisk) which may in the end impact on cardiovascular function. No 
other alterations were observed (Figure 3.18). As shown on Figures 3.19 and 3.20, experimental 
animals fed the HFD indicated no changes in collagen deposition (fibrosis). However it was 
interesting to note that the animals fed the SD in the presence of a tumour (S+T) had 
significantly less (1.23 ±0.20, p< 0.001) fibrosis than those fed the SD alone (2.40±0.23). This 
was an unexpected result considering that the cytokines and adipokines measured for this group 
did not significantly change. 
 
Figure 3.18: H&E histological stains of heart tissue sections from mice fed a standard 
(S) or high fat diet (H) for ±12 weeks, and/or inoculated with cancer cells from eight 
weeks. Representative images of 5 µm thick heart sections picked at random and stained for 
structural defects. 4-5 images from three different mice per group were assessed. Interstitial 
congestion is indicated by the asterisk. Magnification and scale bar: 10x and 100 µm (entire 
section) and 40x and 500 µm (enlargement). Purple colour- nucleus and pink colour – 
cytoplasm.  
 
* 
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Figure 3.19: Picrosirius red histological stain of heart tissue sections from mice fed a 
standard (S) or high fat diet (H) for ±12 weeks, and/or inoculated with cancer cells from 
eight weeks. Representative images of 5 µm thick heart sections picked at random and 
stained for collagen deposition (fibrosis). 4-5 images from three different mice per group were 
assessed. Magnification and scale bar: 10x and 100 µm (entire section) and 40x and 500 µm 
(enlargement) Red colour – fibrosis (collagen I and II), yellow colour - cytoplasm, brown, grey 
or black colour- nucleus. 
 
 
Figure 3.20: Percentage fibrosis in the myocardium of mice fed a standard (S) or high 
fat diet (H) for ±12 weeks, and/or inoculated with cancer cells from eight weeks. 4-5 
images from three different mice per group were quantified for fibrosis using the colour 
threshold of Image J analysis software. Data is represented as median ± SEM (n=3). 
***p<0.001 (versus S).  
 
Stellenbosch University  https://scholar.sun.ac.za
 56 
 
3.4.3 The effect of a high fat diet and cancer on apoptotic protein expression 
To evaluate apoptotic cell death within the experimental groups, caspase-3 and PARP protein 
expression was semi-quantitatively measured by Western blotting. As indicated in Figure 3.21 
below, no meaningful changes in the expression pattern of these proteins was evident. Since 
TNF-α is a pro-inflammatory cytokine that has previously been associated with apoptosis in 
different contexts, the insignificant results obtained may explain why no apoptosis was present. 
 
 
 
Figure 3.21: Relative apoptotic protein expression of mice fed a standard (S) or high fat 
diet (H) for ±12 weeks, and/or inoculated with cancer cells from eight weeks. 
Representative graphs and western blot images of full-length caspase-3 and PARP are 
illustrated. Protein expression was normalized to total protein and presented as a fold change 
relative to controls (S or H). All values are presented as mean ± SEM (n=4). Abbreviations: AU 
- arbitrary units. 
 
3.4.4 The effect of a high fat diet and cancer on oxidative stress parameters  
Similarly to the results obtained above, no changes were observed for CDs and MDA in any of 
the experimental groups (Figure 3.22). It is therefore possible that the different experimental 
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approaches induced in the animals was not severe enough to induce molecular changes that 
were expected. 
 
 
Figure 3.22: Oxidative stress parameters from mice fed a standard (S) or high fat diet 
(H) for ±12 weeks, and/or inoculated with cancer cells from eight weeks. Heart tissue 
lysates were used to evaluate the expression of early (conjugate dienes) and late 
(malondialdehydes) markers of lipid peroxidation. Data is represented as mean ± SEM (n=5-
6). 
 
3.5  Establishing a condition of obesity, cancer and acute cardiotoxicity 
Now that a model of co-morbidity (obesity and cancer) has already been established, this study 
then introduced an additional factor being chemotherapy. Since this study induced breast cancer 
in this model, DOX treatment was utilized to initiate acute cardiotoxicity. Thus, each of the 
above four groups were further divided into two, to create eight different treatment groups. Our 
object in this final section was to determine whether these three inflammatory conditions 
(obesity, cancer and cardiotoxicity) influence one another, whether they make each other worse 
and what impact do they have on body weight and the heart. 
3.5.1  Body weight 
As demonstrated in the figure below, major differences were found between groups S+D when 
compared to H+D, as well as groups H+D when compared to H+T+D (Figure 3.23). When 
looking at groups S+D versus H+D, the common factor is DOX treatment while the difference 
is the diet. Therefore, in this instance, the SD (19.05 ± 0.23 g, p < 0.001) fed experimental 
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animals lost more weight that those fed a HFD in the presence of DOX (25.02 ± 0.84 g) during 
this period (Figure 3.24B). Not only did the animals in group H+D have a greater weight, 
they’re percentage body weight increase was maintained (Figure 3.24C), as well as the 
percentage adiposity (Figure 3.24D). Similarly, when looking at groups H+D versus H+T+D, 
the common factor is the HFD and DOX treatment while the difference is the presence of a 
tumour. In this case, the H+T+D group lost significantly more weight than group H+D (Figure 
3.23). However, the final body weight data as well as the percentage gonadal adiposity reveals 
that in the presence of a tumour and/or DOX treatment, animals fed the HFD significantly lost 
weight and adiposity when compared to the HFD fed animals alone. These results thus suggest 
that cancer and DOX treatment influences body weight negatively. 
 
 
Figure 3.23: Percent body weight gain overtime of mice fed a standard diet (S) or high 
fat diet (H) for ±12 weeks, and/or inoculated with cancer cells from eight weeks 
(represented by the vertical dotted line), and /or treated with DOX (represented by the grey 
shaded area). Body weight data was recorded twice a week from the start of the respective 
diets and the inoculation of tumours until the end of the treatment protocol with DOX. Data is 
represented as mean + SEM (n=8-10). ****p<0.0001 (versus S+D), ####p<0.0001 (versus H+D).  
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Figure 3.24: Biometric parameters of mice fed a standard (S) or high fat diet (H) for ±12 
weeks, and/or inoculated with cancer cells from eight weeks, and/or treated with DOX. 
(A) Initial body weight, (B) final body weight before euthanasia, (C) percentage (%) body 
weight gain and (D) percentage (%) gonadal adiposity of experimental groups. Data is 
represented as mean ± SEM (n=8-10). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Abbreviations: g – grams. 
 
3.5.2 Food consumption and water intake  
To complement the data obtained above, food (Figure 3.25) and water (Figure 3.26) 
consumption was evaluated. Here we demonstrate that group S+T+D (53.50 ± 2.47 kcal, 
p<0.01) consumed significantly less food when compared to group S+D (59.69 ± 0.94 kcal). 
This was an interesting observation considering that the final body weight did not change 
between these two groups. Water consumption was elevated between group H+T+D (30.01 ± 
1.19 ml, p < 0.05) when compared to group H+D (20.95 ± 0.54 ml). 
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Figure 3.25: Weekly food consumption in mice fed a standard (S) or high fat diet (H) for 
±12 weeks, and/or inoculated with cancer cells from eight weeks (represented by the 
vertical dotted line), and/or treated with DOX (represented by the grey shaded area). Food 
intake was measured weekly for each group to determine the average kilocalories (kcal) 
consumed. Data is represented as mean + SEM (n=8-10). **p<0.01 (versus S+T+D). 
Abbreviations: kcal – kilocalories. 
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Figure 3.26: Weekly water consumption in mice fed a standard (S) or high fat diet (H) for 
12 weeks, and/or inoculated with cancer cells from eight weeks (represented by the 
vertical dotted line), and/or treated with DOX (represented by the grey shaded area). Water 
intake was measured daily but evaluated weekly for each group to determine the average 
amount of water consumed. Data is represented as mean + SEM (n=8-10). *p<0.05 (versus 
H+T). Abbreviations: ml – millilitres. 
 
3.5.3 Fasting blood parameters 
This study found no major changes in fasting blood glucose (Figure 3.27A), triglycerides 
(Figure 3.27B), lactate (Figure 3.27C) and TNF-α (Figure 3.27D) in any of the groups 
compared. However, significant changes were however observed with IL-6 (Figure 3.27E) and 
leptin (Figure 3.27F) concentrations between groups H and H+T+D. While IL-6 levels 
increased (126.90 ± 34.92 pg/ml, p < 0.05), leptin levels declined (3277.00 ± 1541.00 pg/ml) 
in the HFD group with cancer and DOX when compared to animals fed a HFD alone (IL-6: 
24.17 ± 5.59 pg/ml; leptin: 11671.00 ± 4538.00 pg/ml, p < 0.05). These results therefore suggest 
that being obese with the complication of cancer with chemotherapy greatly increases 
inflammation. However due to the significant weight loss experienced by these animals, it is 
understandable why the levels of leptin declined. 
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Figure 3.27: Fasting blood parameters of mice fed a standard (S) or high fat diet (H) for 
±12 weeks, and/or inoculated with cancer cells from eight weeks, and/or treated with 
DOX. Mice were starved for 12 hours prior to euthanasia to determine (A) glucose, (B) 
triglycerides, (C) lactate, (D) TNF-α, (E) interleukin-6 and (F) leptin levels. Data is represented 
as mean ± SEM (n=5-6). *p<0.05.  
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3.6 Effect of obesity, cancer and doxorubicin therapy on the heart  
3.6.1 The impact of diet-induced obesity, cancer and doxorubicin therapy on the cardiac 
hypertrophy index  
DOX-induced cardiotoxicity has previously been associated with left ventricular hypertrophy 
which entails the enlargement of the heart and the death of cardiomyocytes. This study shows 
that the heart weight of group H+T+D was significantly reduced (0.10 ± 0.007 g, p < 0.05) 
when compared to group H (0.13 ± 0.005 g) (Figure 3.28A). The heart-to-body weight ratio 
was used to examine potential hypertrophy in these experimental groups however, no changes 
of this aspect were observed (Figure 3.28B). According to these results, pathological 
hypertrophy was not present but possibly cardiac atrophy took place considering that DOX-
induced hypertrophy is better associated with the chronic form of cardiotoxicity rather than the 
acute form. 
Figure 3.28: Cardiac hypertrophy index of mice fed a standard (S) or high fat diet (H) for 
±12 weeks, and/or inoculated with cancer cells from eight weeks, and/or treated with 
DOX. (A) Heart weight and (B) heart-to-body weight ratio of experimental groups. Data is 
represented as mean ± SEM (n=8-10). *p<0.05. Abbreviations: g – grams, AU-arbitrary units. 
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3.6.2 The effect of a high fat diet, cancer and doxorubicin therapy on myocardial 
ultrastructure and collagen deposition 
Although the hypertrophy index revealed no changes in any of the groups, microscopic changes 
within the tissue was further analysed for potential changes in myocardial ultrastructure (Figure 
3.29) and the presence of fibrosis (Figures 3.30 and 3.31). It was only in group H+T+D did this 
study observe potential infiltration and distortion of the heart tissue (displacement of 
intracytoplasmic vacuoles) however, this observation was mild. Additionally no fibrosis was 
observed. 
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Figure 3.29: H&E histological stains of heart tissue sections from mice fed a standard 
(S) or high fat diet (H) for ±12 weeks, and/or inoculated with cancer cells from eight 
weeks, and/or treated with DOX. Representative images of 5 µm thick heart sections picked 
at random and stained for structural defects. 4-5 images from three different mice per group 
were assessed. Interstitial congestion is indicated by the asterisk. Inflammation infiltration is 
indicated by arrowhead. Magnification and scale bar: 10x and 100 µm (entire section) and 40x 
and 500 µm (enlargement). Purple colour- nucleus and pink colour – cytoplasm.  
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Figure 3.30: Picrosirius red histological stain of heart tissue sections from mice fed a 
standard (S) or high fat diet (H) for ±12 weeks, and/or inoculated with cancer cells from 
eight weeks, and/or treated with DOX. Representative images of 5 µm thick heart sections 
picked at random and stained for collagen deposition (fibrosis). 4-5 images from three different 
mice per group were assessed. Magnification and scale bar: 10x and 100 µm (entire section) 
and 40x and 500 µm (enlargement) Red colour – fibrosis (collagen I and II), yellow colour - 
cytoplasm, brown, grey or black colour- nucleus. 
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Figure 3.31: Percentage fibrosis in the myocardium of mice fed a standard (S) or high 
fat diet (H) for ±12 weeks, and/or inoculated with cancer cell from eight weeks, and/or 
treated with DOX. 4-5 images from three different mice per group were quantified for fibrosis 
using the colour threshold of Image J analysis software. Data is represented as mean ± SEM 
(n=3).  
 
3.6.3 The effect of a high fat diet, cancer and doxorubicin therapy on apoptotic protein 
expression 
Considering that DOX is known to induce apoptotic cell death as a mechanism of action, this 
study analysed this form of cell death in all experimental groups. As demonstrated in Figure 
3.32 below, the markers for apoptosis did not significantly change suggesting that the dose 
and/or duration of treatment was not sufficient to trigger apoptosis since acute cardiotoxicity is 
more often associated with myocardial dysfunction rather than myocardial death. 
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Figure 3.32: Relative apoptotic protein expression of mice fed a standard (S) or high fat 
diet (H) for ±12 weeks, and/or inoculated with cancer cells from eight weeks, and/or 
treated with DOX. Representative graphs and western blot images of full-length caspase-3 
and PARP are illustrated. Protein expression was normalized to total protein and presented as 
a fold change relative to controls (S or H). All values are presented as mean ± SEM (n=4). 
Abbreviations: AU - arbitrary units. 
 
 
3.6.4 The effect of a high fat diet, cancer and doxorubicin therapy on oxidative stress 
parameters  
Similarly, to the results obtained above, no changes were observed for the early marker of 
oxidative stress (conjugated dienes) in any of the experimental groups (Figure 3.33). However, 
significant differences in malondialdehyde accumulation was observed between group H+T+D 
(0.009 ± 0.003 μmol/g, p < 0.05) when compared to group H+T (0.003 ± 0.002 μmol/g). This 
increase in malondialdehydes indicates that DOX had an impact on oxidative stress levels. 
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Figure 3.33: Oxidative stress parameters from mice fed a standard (S) or high fat diet 
(H) for ±12 weeks, and/or inoculated with cancer cells from eight weeks, and/or treated 
with DOX. Heart tissue lysates were used to evaluate the expression of early (conjugate 
dienes) and late (malondialdehydes) markers of lipid peroxidation. Data is represented as 
mean ± SEM (n=5-6). *p<0.05. 
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4. DISCUSSION 
Obesity forms part of the development of various pathologies including metabolic disorders 
(Aggoun, 2007), cardiovascular diseases (Poirier et al., 2006), and the development of cancer 
(Basen-Engquist & Chang, 2011). In this context, obese women are often the leading group 
at risk for developing breast cancer (Yung & Ligibel, 2016). Obesity is a pro-inflammatory 
disease that is believed to assist in the angiogenesis and metastasis of cancer cells. This further 
results in the dysregulation of cytokines in the system (Matthews & Thompson, 2016) where 
these cytokines often serve as the modulators for cancer proliferation (Gilbert & Slingerland, 
2013). Moreover, lipotoxicity, insulin resistance and excessive fatty acid production are 
indirectly or directly associated with obese patients’ prognosis for breast cancer outcomes 
(Azrad & Demark-Wahnefried, 2014). Clinically, breast cancer is often treated with the 
potent chemotherapeutic agent DOX; however due to its dose-dependent cardiotoxicity, its 
use is limited. Since DOX administration is based on body surface area (BSA), obese patients 
are thus likely to receive higher dosages of DOX. In an effort to reduce the risk of developing 
cardiotoxicity within obese cancer patients, an arbitrary dose-capping for DOX has been 
implemented to prevent the adverse effects associated with DOX therapy in the heart 
(Lyman, 2011; Hall et al., 2013). Furthermore, considering that obesity, cancer and 
cardiotoxicity are associated with inflammation and oxidative stress, the risk of 
cardiovascular complications increases. As cancer needs to be treated aggressively, clinicians 
are faced with the dilemma of treating cancer knowing the risks for cardiotoxicity. This leads 
to a reduced efficacy of treatment and a cancer-free survival in the obese-cancer population 
due to dose-capping (Lopes- Serrao et al., 2011). The rationale for obesity being a risk factor 
for developing DOX-induced cardiotoxicity is under speculation due to limited research on 
the relationship between DOX and the state of obesity. Being overweight or obese greatly 
impacts on the pharmacokinetics of DOX since it has been shown that DOX within the plasma 
of obese patients is retained for extended periods (Ritzmo et al., 2007). Since obese patients 
are already at increased risk of cardiovascular damage, the treatment of cancer with DOX 
can potentially accelerate the development of cardiotoxicity. As a result, obesity has not only 
become a risk factor for cardiovascular disease and cancer development, it is now a risk factor 
for the development of cardiotoxicity due to cancer treatment regimens (Puma et al., 2008). 
In the experimental design of the current model, it was observed that the above stated diseases 
are either studied in isolation or in the context of DOX therapy, in vivo models often do not 
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have tumours, and therefore the effect of the cancer is not taken into account (Zhu et al., 2010). 
In the current study, we aimed to establish a model of cancer in an obese state to not only 
determine how these diseases together impact on one another but most importantly, how they 
affect the myocardium. It was thus hypothesised that diet-induced obesity increases the risk 
for developing acute DOX-induced cardiotoxicity. 
4.1 Increased fat in the diet induced obesity 
The major difference between the two diets used in this study was the fat content which 
accounted for 60% of calories in the high fat diet (HFD) versus a mere 10% contained in the 
standard diet (SD). The increase in food intake in the HFD group (Figure 3.3) resulted in a gain 
in body weight (Figure 3.2B) by the end of the study. The fat content in this diet consisted 
largely of soybean oil and lard which accounted for the higher calorie intake per day (Ulman, 
2011). As it happens in humans, an increase in calorie intake without physical activity results 
in a gain in body weight and an increase in fat accumulation (adiposity) as observed in this 
study. Adipose tissue in this context thus becomes important because it is an essential and 
highly metabolic organ that secretes factors such as cytokines and adipokines with key 
endocrine functions (Kershaw & Flier., 2004). Under obese conditions, it is known that 
adipocytes undergo hyperplasia to store the excess fat accumulated and as a result causes 
dysregulated adipokine expression (Manna & Jain., 2015). Similarly to our observations, the 
increase in adiposity (Figure 3.2D) in the HFD group is related to increased fat accumulation. 
This was further exemplified by the abnormally high levels of glucose (Figure 3.5A) and leptin 
concentrations (Figure 3.5F). Hyperleptinemia is a direct consequence of obesity (Leopoldo 
et al., 2016; O’Donnell et al., 2000), and may play a role in mediating type 2 diabetes mellitus 
(T2DM) in obesity. While leptin in adipocytes prevents the uptake of glucose, inhibits lipolysis 
and impairs lipogenesis; in hepatocytes, leptin induces insulin-like effects by regulating the 
insulin-signaling pathway. It is therefore possible that there is cross-talk between leptin and 
insulin signaling, potentially making hepatocytes more sensitive to insulin in this context. 
Considering that obesity is an inflammatory disease, it was expected that the pro-inflammatory 
cytokine levels of TNF-α and IL-6 would be elevated, however this was not the case. Similar 
results were obtained in a study conducted by Pettersson and colleagues (2012) who showed 
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that female C57BL6 mice fed the same HFD as in the current study displayed reduced plasma 
IL-6 concentrations when compared to their male counterparts. It was concluded that estrogen 
may have played a significant role in this scenario as this hormone is known to offer protection 
and reduce inflammation. 
 
4.2 Effect of obesity on the heart 
Obesity is a known independent risk factor for the development of CVD because excess weight 
may cause changes within the heart that requires it work harder to send blood to all the cells 
in the body. Although the HFD used in this study produced phenotypically obese experimental 
animals, no overt changes occurred within the heart weight (Figure 3.6A). Since body weight 
serves as the standardising value to evaluate the change in heart weight, the reduced heart-to- 
body weight ratio (cardiac hypertrophy index) (Figure 3.6B) in this study, was due to the higher 
final body weight rather than the actual heart weight in the HFD group. Considering the events 
that have to occur for cardiac remodeling to take place during obesity, it was unlikely to have 
occurred within the 12 week period of the study. These sentiments are echoed by Rennison and 
colleagues (2007) who illustrated an increase in body weight without detrimental changes to 
the myocardium. This suggests that it is difficult to distinguish between the adaptation and 
maladaptation phase of obesity’s effect on the heart (Harmancey et al., 2008). 
Histological analysis (Figure 3.7) also revealed no signs of pathological hypertrophy between 
the two groups although this can be attributed to other factors since this study only assessed the 
whole heart to determine the ratio. Others (Lin et al., 2000; Laflamme et al., 2012; Kumar et 
al., 2014) have suggested the use of tibia length or brain weight which are better parameters 
to determine the cardiac hypertrophy index since the body weight changed throughout the 
study. Moreover, obesity is associated with the onset of fibrosis in the heart and forms part of 
the structural changes that occur due to obesity (Abel et al., 2008). Although the link between 
obesity and cardiac fibrosis has already been well-established, the pathophysiologic basis for 
fibrotic interstitial remodeling in the hearts of obese subjects remains poorly understood. The 
activation of fibroblasts has previously been shown to play a major role in obesity-associated 
fibrosis; however, inflammatory cells, cardiomyocytes and vascular cells may also trigger 
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fibrogenic signaling (Cavalera et al., 2014). Molecular processes including the renin- 
angiotensin-aldosterone system, induction of transforming growth factor-β, oxidative stress, 
advanced glycation end-products, endothelin-1, Rho-kinase signaling, leptin-mediated action 
and upregulation of matricellular proteins, have all been implicated in regulation of the fibrotic 
response in obesity and may play a role in the development of fibrosis in models of obesity and 
metabolic dysfunction. Based on the above cited studies, it still remains unclear whether the 
observed myocardial changes are as a direct effect of increased adiposity, or are reflective of 
the consequences of the many pathophysiologic associates of obesity. As we did not observe 
increased fibrosis in the HFD group (Figures 3.8 & 3.9), this can be explained by the fact that 
the development of cardiac fibrosis occurs late and requires prolonged feeding of a high-fat, or 
a high-fat/high-sugar diet for 6–16 months (Zibadi et al., 2009; Qin et al., 2012). High-fat diets 
may be even less effective in inducing cardiac fibrotic changes as Calligaris and co-workers 
(2013) found that male C57/BL6J mice required feeding with a HFD for 16 months to develop 
significant cardiac hypertrophy and myocardial fibrosis. 
 
Numerous studies have demonstrated apoptosis of cardiomyocytes in experimental models 
of obesity (Barouch et al., 2006). This mechanism of cell death is one of three that may be 
stimulated when cardiomyocytes become damaged (Cook & Poole-Wilson, 1999). The 
accumulation of fatty acids and triglycerides in the myocardium may induce toxic effects on 
cardiomyocytes that eventually leads to their dysfunction and death (Alpert et al., 2014). It 
is therefore likely that since our model failed to demonstrate inflammation (Figure 3.5 D & 
E), fibrosis (Figures 3.8 & 3.9) and oxidative stress (Figure 3.11), all of which have been 
shown to induce apoptotic activity, this model was unlikely to demonstrate evidence of 
apoptosis (Figure 3.10). In summary, while the HFD used in this study was effective in 
inducing obesity which was accompanied by some metabolic changes, the duration of the 
study was inadequate to induce many of the obesity-related pathophysiological perturbations 
particularly those that put the myocardium at risk. 
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4.3 Cancer in an obese state induces body weight loss and increased inflammation 
There are many other diseases that have been linked to obesity including various cancers 
(Ceschi et al., 2007); and the novelty in the current model was the induction of breast cancer 
which was critical in understanding the biological interaction of two diseases in one 
experimental model. A person's risk of cancer depends on various factors, including those 
you cannot change such as age and genetics. Other factors that can cause cancer, whether 
that's obesity, smoking or the sun, increases a person's risk of cancer, however that does not 
mean that a person will definitely develop cancer. The majority of all the evidence that links 
obesity to cancer risk comes from large observational studies, however there is difficulty in 
interpreting such studies due to the fact that obese or overweight people may differ from lean 
people in ways other than their body fat and it is therefore difficult to establish that the cause 
of cancer was due to obesity. Regardless of this limitation there is consistent evidence that 
indicates that higher amounts of body fat are associated with increased risk of a number of 
cancers. There are several mechanisms that have been implicated to explain how obesity may 
increase the risk of different cancers. Obese people are known to have chronic low-grade 
inflammation, which can over time, cause DNA damage that leads to cancer development. 
Furthermore, overweight and obese individuals are more likely than normal-weight 
individuals to have disorders that are associated with or that cause chronic inflammation that 
are risk factors for certain cancers. For example, obese individuals have been shown to have 
elevated insulin and IGF-1 levels which can promote the development of colon, kidney, 
prostate, and endometrial cancers (Hsieh, 2011) possibly through cell growth regulators that 
include mTOR and AMPK. Adipose tissue during obesity produces excessive amounts of 
estrogen which has been linked with increased risks of breast, endometrial and ovarian 
cancers (Hsieh, 2011; Suzuki et al., 2012). Adipocytes also secrete adipokines such as leptin 
which promotes cell proliferation during obesity, and adiponectin, which is less abundant in 
obese individuals and has anti-proliferative effects. 
 
In the present experimental model, the presence of a tumour negatively affected body weight 
gain over time (Figure 3.12). The most significant weight loss was observed in the HFD 
group (Figure 3.13B) despite maintaining increased food intake (Figure 3.14), suggesting 
Stellenbosch University  https://scholar.sun.ac.za
  
75 
 
 
that the presence of a tumour may have accounted for the body weight loss. In oncology, 
cancer cells are known to utilize glucose as their preferred source of energy while generating 
lactate. This is known as the Warburg effect, and why cancer cells choose to use a less 
efficient system (compared to oxidative phosphorylation) even in the presence of oxygen 
remains debatable. Since our model did not display considerable changes in fasting glucose 
(Figure 3.16A), triglyceride (Figure 3.16B) and lactate (Figure 3.16C) levels, is it difficult to 
interpret our findings against the currently available literature. What was interesting to note 
from our observations was that the significant decrease in adiposity (Figure 3.13D) coincided 
with a trend towards a decline in triglyceride levels, albeit insignificant. Considering that 
most cancer researchers focus on glycolysis, it is reasonable to speculate that the decrease in 
adiposity may have been attributed to the reduction of leptin levels (Figure 3.16F) which 
inhibits lipolysis in obesity. The relevance of fatty acid oxidation for cancer cell function has 
thus not been carefully examined, and its relevance in this context remains to be elucidated. 
In accordance with the literature (Kumari et al., 2016), this study also observed significantly 
elevated levels of IL-6 in the HFD group with a tumour (Figure 3.16E). IL-6 is one of the 
main cytokines secreted by tumour cells within the microenvironment that is overexpressed 
in virtually of types of cancers. In this context, IL-6 promotes tumour development by 
regulating various signaling pathways and hallmarks of cancer. In addition, IL-6 provides 
protection for cancer cells against therapy- induced DNA damage, apoptosis and oxidative 
stress by initiating repair processes and/or anti- apoptotic and anti-oxidant mechanisms. Since 
cancer, like obesity is an inflammatory disease, the inhibition of IL-6 or its regulatory 
signaling pathways may potentially be an effective treatment strategy for cancers associated 
with increased IL-6 concentrations. Considering that inflammation is closely related to 
oxidative stress, which can stimulate apoptotic cell death; this was not the case in this study. 
The myocardial ultrastructure was similar to the control (Figure 3.18) and no oxidative stress 
(Figure 3.22) nor apoptosis (Figure 3.21) was observed. Although numerous studies have 
demonstrated myocardial damage in other inflammatory models (Sishi et al., 2013; 
Eijsvogels et al., 2012), it is likely that in this scenario, the duration of the study was too 
short for these adverse effects to be seen. 
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4.4 DOX treatment and tumour presence decrease body weight 
DOX treatment is linked to the secondary effect of development of cardiotoxicity and its 
proposed that obesity is a contributing risk factor to this state (Blaes et al., 2017). Obesity is a 
known risk factor for the development of DOX-induced cardiotoxicity (Pai & Nahata., 2000). 
In a meta-analysis by Guenancia et al., (2016) being overweight and obesity have showed to 
have a predisposing effect on the development of cardiotoxicity due to anthrayclines of which 
DOX is a part of. It was suggested that the findings were to be taken with close observation as 
it included various studies and the methodology was questioned with obesity being linked to 
various co-morbidies (Cheraghi et al., 2017). 
Firstly, DOX’s effect on body weight was evaluated from week 10 (Figure 3.23). From the 
results the HFD induced-obesity and DOX effect on the mice final body weight showed a 
significant decrease in body weight, indicating that DOX treatment in the high fat group 
showed a slight reduction (Figure 3.24B). In a study by Biondo and colleagues (2016), using 
rats that were treated with DOX showed a decrease in body weight and adiposity, confirming 
this similar observation, the diet is one of the main factors to a reduced body weight increase 
(Figure 3.24C). This show-cases that DOX has the ability to affect the metabolic state of the 
animals since adipose tissue is an endocrine organ, which is involved in the regulation of 
energy balance. Throughout week 11 and week 12, when mice approximately received DOX 
treatment, DOX did not affect the food intake (Figure 3.25) or the water intake (Figure 3.26) 
amongst the experimental groups. DOX increased glucose (Figure 3.27A) but decreased 
plasma leptin (Figure 3.27F). The elevated fasting plasma IL-6 levels (Figure 3.27E) in the 
DOX treated groups is a possible indication of the DOX effect on the onset of the 
inflammatory state. DOX has the ability activate the production of cytokines and activate 
cytotoxic T lymphocyte and this activate the natural killer (NK) (Haskill, 1981). TNF-α is 
another pro-inflammatory cytokine upregulated in the obese condition (Van Kruijsdijk et al., 
2009). Plasma TNF-α like plasma Il-6 showed that the DOX treated mice irrespective of diet 
showed a trending increase in the experimental groups (Figure 3.27 D). This shows that DOX 
has the ability to activate the immune system (Tacar et al., 2013), whether it is due to a natural 
response due to DOX being foreign or whether it is due to the mechanism by which DOX 
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affects both cancer and non- cancerous cells is unknown. Although only two inflammatory 
markers were evaluated this shows promising results that indeed supports the theory that the 
chronic inflammatory state is upregulated in the presence of obesity, cancer and DOX. This 
could be seen as the linkage mechanism by which early-stage cardiotoxicity can occur. 
However, in the study no special inflammatory stain was used to quantify this observation 
within the heart tissue and only the structural changes and semi-quantified inflammation 
infiltration was evaluated (Figure 3.29). The increase in circulating inflammation markers in 
the presence of DOX can however be related to the contribution that the innate immune 
system which is upregulated by DOX (Gambardella et al., 2017). From the results, there is a 
plausible interlinked relationship between cancer and obesity with its overlapping 
observation of upregulated inflammation but whether it has a direct link with the heart is not 
clear in the outcomes of the study. However, the relation of the decrease in plasma leptin with 
DOX is not well understood, and whether it is beneficial or detrimental requires further 
analysis. Exogenous administrated leptin has been shown to be cardioprotective after 
Ischemia-reperfusion (I/R) injury by the activations of RISK pathway activating PI3K-AKT 
and MAPK pathway which is involved in the protection of the heart (Smith et al., 2006). This 
observation is due to exogenous leptin. For this study we evaluated leptin that is produced 
internally by adipose tissue and therefore could deflect different outcomes due to excessive 
production by adipose tissue. 
 
4.5 Effect of chemotherapeutic treatment during cancer in an obese context 
DOX is a common therapeutic agent for the treatment of various cancers. As potent as it is, 
it is also associated with many side effects, particularly toxicity of the heart. Not only is DOX 
known for its ability to produce free radicals, cardiomyocyte apoptosis has also been 
demonstrated leading to structural disorganization ultimately resulting in the enlargement of 
the heart in the long term (Tacar et al., 2013). Considering that cancer can cause significant 
body weight loss, DOX can exacerbate this condition as it has been shown to activate protein 
degradation pathways (Sishi et al., 2013) that contributes to overall body or organ weight loss. 
While DOX treatment alone did not have an impact on body weight loss irrespective of diet, 
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the presence of a tumour greatly impacted the final body weight in the HFD group that received 
DOX treatment (Figure 3.24B). This group also displayed reduced adiposity (Figure 3.24D) 
and leptin concentrations (Figure 3.27F) but elevated IL-6 levels (Figure 3.27E). Although it 
may appear that the loss of weight in the obese context may be beneficial, the sustained 
systemic inflammation may have adverse effects in the long term if not reduced or regulated. 
In support of our observations, Fujita and colleagues (1996) elegantly demonstrated the role 
that chronic IL-6 exposure plays in stimulating protein breakdown, whereas van Hall and 
colleagues (2003) showed IL-6’s role in inducing lipolysis. Similarly to the body weight loss 
observed in the HFD fed group inoculated with cancer cells and treated with DOX, the final 
heart weight mass was also reduced (Figure 3.28A). While this observation at face value may 
indicate cardiac atrophy, various factors have to be considered such as the study duration and 
the duration of DOX treatment. Since there was no functional evaluation of the heart it is 
difficult to ascertain whether DOX had any effect on the heart during DOX administration or 
immediately after. Moreover, we observed no severe structural adaptations other than mild 
displacement of intra- cytoplasmic vacuoles and infiltration (Figure 3.29). With regards to 
fibrosis, there are two different types: replacement fibrosis that occurs when cell death of 
tissue occurs; and reactive fibrosis, which is when an increase in work load is required (de 
Jong et al., 2012), both of which can induce irregular cardiovascular function. In the current 
study we were unable to distinguish between the two since neither fibrosis (Figures 3.30 & 
3.31) nor apoptosis was evident (Figure 3.32). Apoptotic activity can be triggered by elevated 
oxidative stress which can be triggered by increased inflammation. Although inflammation 
may have attributed to the oxidative stress shown in our model (Figure 3.33), the oxidative 
stress observed may not have been sufficient to stimulate apoptotic cell death as expected. In 
summary, the aim of the study was to establish the relationship between cancer in an obese 
context, and what impact these inflammatory diseases have in contributing to the 
development of acute DOX-induced cardiotoxicity. While we were able to provide evidence 
as to how a diet high in fat induces obesity and its impact on some metabolic parameters, it 
was difficult to provide conclusions about the diets effect on the heart. The complication of 
cancer in this context produced contrasting effects. A considerable amount of body weight 
and adiposity was lost, and consequently resulting in a decline in adipokine but elevated 
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cytokine expression. Despite these changes, no impacted on any of the cardiovascular 
parameters evaluated in this study. When DOX treatment was introduced, similar effects 
were observed with the exception of increased oxidative stress damage (Figure 3.34). 
Therefore in conclusion, future research is warranted to better understand the complexities 
involved during the initiation and progression of cancer in an obese environment, and what 
impact chemotherapy in this scenario would have on cardiovascular structure and function. 
 
Figure 3.34: Summary of the main findings from the study: demonstrating the 
effects of a high fat diet, breast cancer and DOX treatment on the heart and the various 
pathways affected. Solid lines are confirmed observation and dashed lines are 
proposed outcomes. Up arrowheads indicate increase/activation and down 
arrowheads indicate a decrease/inhibition. Abbreviations: DOX - Doxorubicin, TNF-α 
- Tumour Necrosis Factor-alpha, IL-6 - interleukin- 6. 
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5. Limitations and future directions 
One of the main limitations in this study was the fact that we did not evaluate cardiovascular 
function which would have provided additional information with regards to how the heart is 
performing under the different experimental conditions. To further explore myocardial damage 
to supplement the histological stains performed, markers of damage such as cardiac troponins 
or brain natriuretic peptide could have been included to add value to this study. The presence 
of adiponectin and its relationship with leptin in the context of obesity-induced cancer would 
assist in the improved understanding of the molecular events take place. Due to financial 
constraints and logistical issues, the addition of the above was thus not possible. 
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7. APPENDICES 
7.1 Appendix A: Supplementary Results 
7.1.1 Tumour volume  
The second disease state to establish in the co-morbid model was to introduce E0771 murine 
breast cancer cell in the tumour bearing mice after eight weeks on the diet. The interest for the 
study was not the tumour but it was important to establish that the mice had grown a tumour 
and that the chemotherapeutic treatment with Doxorubicin (DOX) was effective in mimicking 
the clinical setting.In the results (Figure 7.1), we were able to show that the accumulative 
12mg/kg DOX was able to reduce the growth rate in both the SD mice compared to the HFD 
mice compared to vehicle control. Specifically looking at 27 Days after the inoculation of the 
tumour (Figure 7.2A) S+T+V vs S+T+D (1379.73 ± 301.54 mm3 vs 677.12 ± 159.97 mm3 
p<0.001) and (Figure 7.2D) H+T+V vs H+T+D (2043.52 ± 446.62 mm3 vs 1569.28 ± 190.05 
mm3 p<0.001) show that DOX treated mice had a reduced tumour volume. 
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Figure 7.1:E0771 breast cancer (Tumour) Volume of mice fed a standard (S) or high fat 
diet (H) and that were inoculated with a tumour and received doxorubicin treatment 
All tumour bearing female C57Bl6 mice at eight week on diet were injected with 1.2 X 105 
E0771 breast cancer cells into the 4th mammary pads, growing volume per day is shown. 
Vertical lines (red dotted lines) projects the average day on which mice receive the first (±Day 
15), second (±Day 19) and third (±Day 23) treatment injection of Hank’s balanced salt solution 
(HBSS= vehicle control) or DOX. The horizontal red dotted line represent the approximate 
average tumour volume (200-300mm3) before first treatment injection occurred. . 
Abbreviations: S- Standard diet, H- High Fat diet, T- Tumour, D-Doxorubicin 
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DOX used in the study was effective in reducing the rate at which the tumour was growing 
however, the HFD mice showed a larger tumour volume for both DOX and vehicle treatment 
(Figure 7.2B &C). The tumour volume and growth analyses was not part of the scope of the 
study and was additional to show that DOX was effective in its primary function in treating the 
tumour and that the tumour was present in the tumour bearing groups. 
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Figure 7.2: E0771 breast cancer (Tumour) Volume of mice fed a standard (S) or high fat 
diet (H) and that were inoculated with a tumour and received doxorubicin treatment. 
Representing A) Standard diet fed mice B) vehicle control mice C) DOX treated mice and D) 
High fat fed mice. Female C57Bl6 mice at eight week on their respective diets (Standard or 
high fat) were injected with murine E0771 breast cancer cells into the mammary pads and 
served as the tumour groups. Ventricle lines (red dotted lines) projects the average day on 
which mice receive the first (Day 15), second (Day 19) and third (Day 23) treatment injection 
of Hank’s balanced salt solution or DOX. The horizontal red dotted line represent the 
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approximate minimum tumour volume before first treatment injection (200-300mm3).  Data 
represented as mean ± SEM, (n=8-10). Abbreviations: S- Standard diet, H- High Fat diet, T- 
Tumour, D-Doxorubicin 
Mice tumour volumes were compared due to the effect of the specific diet by comparing S+T+V 
vs H+T+V (Figure 7.2A) tumour volume due to diet irrespective of treatment with Hank’s 
balanced salt solution (HBSS= vehicle control). As well as comparing the effect of the diet 
Comparing S+T+D vs H+T+D (Figure 7.2C) tumour volume due to treatment irrespective of 
treatment with DOX. 
Total Protein stain free membrane 
        
    
Figure 7.3: Showing membrane 1, 2, 3 and 4 total protein image of mouse heart tissue 
used for apoptosis protein expression (CAS-3 & PARP) in western blot analysis  
2 
3 4 
1 
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Figure 7.4: Positive staining Controls for fibrosis using Picrosiruis Red stain, Skin and 
colon tissue stained with the same Sirius red as the heart tissue.  
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7.2 Appendix B: Detailed Protocols 
Protocol 1: Cell Culture 
 Cell Culturing 
 Work aseptically by wearing a clean lab coat, washing hands, wearing gloves, lab coat 
cover selves and washing gloves. 
 Spray gloves with 70% ethanol, spring laminar flow hood, as well as anything entering 
the hood with 70% ethanol. 
 
1.1 Cracking a vile and Growth of Cells  
 Thaw a vile of cells from liquid Nitrogen cascade at 37 ºC 
 Add 5 ml of  growth medium (see Appendix C) to T25 flask  
 Pipette 1 ml of cells into flask, close cap and shake (north, south, east, and west) 
 Incubate, 37 ºC with CO2 at 5%  
 Check cell growth and change growth media (see Appendix C), every 2-3 days, until 
cells are 80% confluent then cells are ready to be passaged or used for experimental 
purposes. 
1.2 Passing/ Splitting cells  
 Put medium and trypsin  in water bath at 37 ºC, about 2 tubes each  
 Check for confluence (80% saturation), and then move to the hood.  
 Remove media using 5 ml pipettes, then add: 
o  4 ml trypsin to each T25  
o 8 ml trypsin to each T75 
 Place on shaker for 5 minutes, check that cells are round and detached  
 Add double the medium to neutralize the trypsin 
o  8 ml for T25 
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o 16 ml for T75 
 Transfer all content of flask into 15 ml tube  
 Centrifuge at 1500 rpm for 3 minutes  
 Remove media from tube (supernant), dispose of the media leaving only pellet at the 
bottom. 
 Use new pipette to add 2 ml of media and resuspend pellet gently without causing any 
bubbles. 
 Count cells if seeding density is necessary or if amount of cells are needed to be known 
otherwise , Pipette 1 ml  each into T75 equally and add additional media 
 1.3 Cell Counting  
 Prepare haemocytometer and cover slip by wiping down with 70% ethanol 
 Moisturize haemocytometer to make the surface adhesive for the cover slip to stick with 
out bubbles. 
 Pipette 20 µl of cell resuspension both sides of the haemocytometer undercover slip 
make sure no bubbles have form 
 Count as follows: 
o Only count cells that fall on the Top and left of the counting grid square 
o The more blocks counted the more accurate. 
 Using haemocytometer count as follow using Figure 7.1 as a guide. 
Total amount of cells block A + Total amount of cells block B + Total amount of cells block C 
+ Total amount of cells block D + Total amount of cells block E. 
Divided by total blocks counted = Total cells per 1 mm by 1 mm (on average) 
 Repeat the same for the other side of the haemocytometer average the two values. 
o Total cells (1 mm by 1 mm) x 1000 µl /0.1 µl= cells/ml 
o Once total amount of cells/ml is calculated multiply by the amount of cells 
suspend.  
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o Use the value to calculate how much volume of cell suspend is required to give 
a certain value of cells to seed in flasks for cell growth or used in experiment 
 
 
 
 
 
Figure 7.1. Haemocytometer grid of cell counting  
 
Protocol 2: Tumour preparation and injection 
2.1 Tumour preparation 
Follow cell growth procedure as mentioned in cell culture procedure. Once cells are counted 
use the required volume for 1 500 000 cells of E0711 cells for each mouse made in 250 µl. 
Therefore when injected 1 200 000 cells are injected in 200µl.   
 Centrifuge cell suspend 
 After cell count has been completed centrifuge at 1500 rpm for 3 minutes  
 Add the specific volume of Hank’s balance salt solution to give 6 000 000 cells/ml  
  
 
 
 
 
 
 
 
A B 
C 
D E 
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 Add 250 µl Aliquot suspends into 1 ml Eppendorf tubes and use immediately for 
injections. 
 
2.2 Tumour Injections 
 Place mice under 3% isoflurane in aesthetic chamber. 
  Spray area of injection with 70% ethanol and wipe down. 
  Prepare tumour inject using 1 ml 28 gauge sterile needle and remove any air bubbles. 
 Make suspension to 200 µl ( 1 200 000 cells) 
  Inject into 4th mammary pad of mice until skin bulge.  
 Allow mice to wake up and monitor movement and cognitive response. 
2.3 Tumour growth 
 Every day after injection monitored mice daily for tumour growth by restraining mice. 
 If bulge/ pimple was felt was listed as palpable but not measurable. 
  Once tumour were able to be measured daily tumour measurement were carried out by 
using a digital calliper. 
  Volume of tumour was measure as following: three reading were taken, the largest 
volume served as length (longitudinal) and the smallest volume the width (transverse), 
the third measurement was not used for the calculation.  
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𝑻𝒖𝒎𝒐𝒖𝒓 𝑽𝒐𝒍𝒐𝒖𝒎𝒆(𝒎𝒎𝟑) =  𝟎. 𝟓 × (𝒍𝒆𝒏𝒈𝒕𝒉 ) × (𝒘𝒊𝒅𝒕𝒉𝟐) 
Figure 7.2: Tumour measurement 
 
Protocol 3: Making up Doxorubicin ((DOX) treatment 
100 µl Doxorubicin (4 mg/kg) treatment was given once tumour’s reached volume of 200-300 
mm3 of which they receive 3 intraperitoneal injections every 4th day. Vehicle groups received 
100 µl Hank’s balance salt solution. Mice skin cribbed at neck and held in a way that mice are 
restricted to movement. Using a 28 gauge needle filled with 100 µl of DOX or HSSB injected 
in between nipples in the intraperitoneal cavity on the mouse’s right. If pimples formed mice’s 
left side was injected.  
Table 7.1: Treatment Injection 
Day 0 Day 1 Day 5 Day 9 Day 13 
200-300 m3 DOX(4 mg/kg) 
/Vehicle  
Injection 1  
DOX(4 mg/kg) 
/Vehicle  
Injection 2 
DOX(4 mg/kg) 
/Vehicle 
 Injection 3 
Euthanasia 
 
 
Figure 7.3: Showing injection. Picture Adapted from (Suckow, Danneman & Brayton, 2001) 
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3.1 Material  
 DOX STOCK (5 mg/ml or 5 µg/µl) 
 Hank’s balance salt solution 
 1 ml insulin needle 
3.2 Preparation 
 Weigh mice the day before or the morning before injection  
 Make injection to administer  4 mg/kg(4 µg/g) of DOX for each mouse 
 Calculate: 
 
4 µg⁄g  × weight of mouse (g) = weight of DOX (µg)    …① 
weight of DOX (µg) ÷ 5 µg/µl =amount of µl from DOX stock    …② 
amount of µl from DOX stock + amount of  HBSS= 100 µl for injection.     …③ 
 Injections are given as 100 µl but to compensate for loss of volume when placing in 
syringe and bubble that occur volume is made to 20% or 50% more = 120 µl or 150 µl 
respectively  
 
 amount  from DOX stock (µl) (×1.2) + amount of HBSS (µl) (×1.2) = 120 µl…④ 
o Example:  
 If mouse weight =25.3 g  
 Sub into ① 
 4 µg⁄g × 25.3 g =101.2 µg  
 Sub into ② 
 101.2 µg ÷ 5 µg/µl =20.24 µl  
 Sub into ③ 
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 20.24 µl +  79.76 µl =100 µl  
 Sub into ④ 
 40.5 µl +  159.5 µl = 200 µl  
 Therefore 40.5 µl from DOX STCOK plus 159.5 µl HBSS in 
Eppendorf mix  
 Collect 100 µl of DOX suspension for Eppendorf tube into sterile syringe  
 Place mice under 3% isoflurane sedation  
 Clean mice with ethanol before injection 
 Inject mice intraperitoneal, discard syringe after every use 
 Allow mice to recover and check vitals  
Protocol 4: ProcartaPlex Multiplex Immunoassay  
4.1 Sample Preparation  
 At euthanasia after heart was excised 
 Blood from the chest cavity was collected in EDTA tubes 
 Kept on ice until euthanasia was complete 
 Centrifuge at 2000 rpm at 4 ºC for 10 minutes 
 50 µl Aliquots were prepared and store at -80ºC 
Day before assay was performed plasma aliquots were thawed gradually from -80ºC to -20 ºC 
to 4ºC gradually 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
109 
 
 
4.2 Assay Reagents Preparation 
Table 7.2 Regents supplied in ProcartaPlex Mix & Match Mouse 4-plex Luminex kit 
Quality Reagents Buffer preparations 
2 Antigen standard  
1 Mouse Immune Monitoring Bead Mix  
1 Mouse Immune Monitoring Detection 
Antibody Mix 
 
1 Reading Buffer  
1 Wash Buffer Concentrate (10x) Make 1x. Bring to room temperature, 
vortex for 15 secs. Add 20 ml wash 
buffer concentrate (10x) with 180ml 
dH2O. Store 2-8 C for 6 months 
1 Steptavidin -PE  
1 Universal Assay Buffer  
 PCR 8-tube Strip  
1 96-well flat bottom plate  
2 Plate sealers  
 Controls High  
 Controls Low  
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4.3 Reconstitution of standards and controls 
 Centrifuge the antigen standard vials and controls at 2000 × g for 10 seconds. 
  Add 250 μL of 1x Universal Assay Buffer into each standard or control vial.  
 Gently vortex the vial(s) for 10 seconds and centrifuge at 2000 × g for 10 seconds to 
collect contents at the bottom of the vial(s). 
 Incubate on ice for 10 minutes to ensure complete reconstitution.  
 Note: After reconstitution, standards and controls are ready to be used for the Assay 
Protocol 
 
4.4 Prepare 4-fold serial dilution 
 Prepare a 4-fold serial dilution of the reconstituted standard(s) using the PCR 8- tube 
strip provided.  
 Label tubes Std1, Std2, Std3, Std4, Std5, Std6, and Std7.  
 Follow Serial dilution depicted in Figure 4.1 
 Add 200 μL of the reconstituted antigen standard into the first tube of the strip and label 
as Standard 1 (Std1). 
 Add 150 μL of 1X Universal Assay Buffer into Std tubes 2–7.  
 Transfer 50 μL of the reconstituted antigen standard from Tube 1 into Tube 2 
 Mix by pipetting up and down for a total of 10 times.  
 Transfer 50 μL of the mixed standards from Tube 2 into Tube 3.  
  Mix by pipetting up and down for a total of 10 times. 
 Repeat steps 4–7 for Std tubes 4–7. 
 Add 200 μL of Universal Assay Buffer into tube 8, which serves as a blank. 
 Keep on ice until ready to use. 
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Figure 7.4: Serial Dilution 
 
 Expected values of controls  
o  Control High: S2-S3  
o Control Low: S5-S6 
 Note: All control ranges were evaluated in Universal Assay Buffer and 2 hours 
incubation at room temperature. 
 
4.5 Assay protocol 
 Prepare Antigen Standard 
 Vortex magnetic capture beads for 30 seconds 
 Add 50µl of the magnetic beads to each well, remove liquid 
 Add 25 µl of Universal Assay Buffer to each well  
 Add 25 µl of standards, control or plasma 
 Seal plate incubate with shaking at room temperature for 60-120 minutes 
 Wash beads(3x) 
 Add 25 µl of Detection Antibody Mix(1x) 
 Seal plate. Incubate with shaking at room temperature for 30 minutes 
 Wash beads (3x) 
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 Add 50 µl Streptavidin- Phycoerythrin to each well 
 Seal Plate. Incubate with shaking at room temperature for 30 minutes 
 Wash beads(3x) 
 Add 120 µl of reading buffer 
 Seal Plate. Shake at room temperature for 5 minute 
 Overnight incubation and Read on Magpix ™ system the next day 
 
Table 7.3 Plasma markers analysed using Luminex assay 
Bead/Analyte Name Luminex Magnetic Bead Region Catalogue Number  
Anti-IL-6 Beads  28 EX01A-20603-901 
Anti-TNFαBeads 45 EX01-20607-901 
Anti-IL-10 Beads 13 EPX01A-20614-901 
Anti-Leptin Beads 65 EX01A-26036-901 
 
Protocol 5: Tissue lysate preparation (Oxidative Stress) 
Conjugated dienes (CDs) and Thiobarbituric acid reactive substances (TBARs) assay sample 
preparation used the sample tissue sample preparation step. 
 Thaw ± 20mg of frozen tissue sample in a labelled Eppendorf on ice.  
  Add cold phosphate buffer to each Eppendorf in a 1: 10 ratio of tissue sample (e.g. 
20mg tissue to 200µl p-buffer).  
 Homogenize tissue and sonicate at 10A, 5-10 seconds or water sonicate for 10 minutes. 
 Allow froth to settle (±30 minutes). Once settled Centrifuge for 10 minutes at 12000 
rpm. Take off the supernant and transfer to chilled labelled Eppendorf, discard the pellet. 
Freeze at -80oC or use directly for assay. 
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Protocol 6: Conjugated Dienes (CD) assay  
Work on ice 
 Added 50 µl of cell lysate (prepared in Protocol 5) to centrifuge tubes in a 1:5 ratio 
chloroform + methanol buffer (1:2) 
o 100 µl chloroform + 200 µl methanol 
 Centrifuged at 10 000 rpm for 10 minutes = 2 layers form, transferred 200 µl bottom 
chloroform layer to new centrifuge tube.  
 Leave overnight with Eppendorf lid open in 4°C fridge to allow the nitrogen to 
evaporate.  
  Added 1 ml cyclohexane to centrifuge tube and vortex for  ± 20 seconds  
 Loaded 300 µl Blank (cyclohexane) and samples into UV clear 96 wells (performed in 
triplicate). 
  Read plate at 234 mm absorbance with Multiskan® Spectrum microplate and 
Spectrophotometer (51119200, Thermo Electron Corporation, Massachusetts, USA). 
 
Protocol 7: Thiobarbituric acid reactive substances (TBARS) assay 
7.1 Preparation   
 Add 250 µl of Sodium hydroxide (NaOH) in 10 ml of distilled water (0.1M) 
 Weighed 0.125 g 2-Thiobarbituric acid (TBA) and dissolved in 10 ml of NaOH 
 Weight 0.008 g of Butylated hydroxytroluene (BHT) dissolved in 10 ml of 96% ethanol  
 Added 684.93 µl O-phosphoric acid OPA to 50 ml distilled water (14.6 M) 
7.2 Procedure 
 Set the water bath to 90 °C (fill it to 80%) and used 2 ml Eppendorf tubes open and 
punch holes in their lids. 
 Add 50 µl of sample lysate (prepared in protocol 5) into an Eppendorf tube 
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 Add 6.25 µL of Butylated hydroxytoluene (BHT). 
  Add 50 µL o-phosphoric acids (0.2M) to each sample, Vortex. 
  Add 6.25 µL TBA reagents to each sample, Vortex.  
 Heat at 90 °C for 45 minutes (be strict with time and degrees for each repeat).  
 Place samples in an ice bath for 2 minutes (or until needed) 
 Transfer to 96 wells, use butanol as the blank and read A532 – A572 
7.3 Analysis of results 
Makes use of the Beer lambert Law  
EQUATIONS: 
 Ԑ = 1.54 x 105 
 Inter-assay CV = <8% 
 C = A/ Ԑ 
 Use the absorbance value obtained  and divide by Ԑ to obtain the concentration for each 
sample 
Protocol 8: Tissue lysate preparation and Electrophoresis (Western Blot) 
8.1 Protein extraction 
Work on ice 
 Thaw tissue on ice 
 Using  scissors manually homogenized tissue on ice (± 20 mg)  
  Add 200 µl (1:10 ratio) of RIPA buffer to tissue sample and use tissue homogenizer to 
homogenize tissue working on ice. 
  Once homogenize sonicate tissue for 15 seconds at 10Amps. 
  Allow foam to settle on ice for ± 30 minutes.  
 Centrifuge tissue lysates at 12 00 rpm for 15 minutes (4ºC).  
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 Transfer supernant to chilled Eppendorf tubes and discard pellet 
 Use directly or freeze at -80ºC 
 
8.2 Protein determination 
 Switch on Direct Detect™ Spectrometer (Merck) to allow machine to warm up and 
calibrate humidity. 
 Run direct Detect program under operator  
 Click proteins and buffer for standard –RIPA buffer 
 Add 2 µl of each sample, vortex and it is placed on Direct Detect card and measured, 
RIPA buffer served as blank.  
 Select pre drying of transparent membrane 
 Vertically insert card into slot, card is dried and each sample is measured 
 Protein is determined in mg/ml concentration, which is used in accordance to loading 
40 mg tissue lysate. 
8.3 Preparation of tissue lysates  
 Appropriate amount of tissue lysate is determined using protein determination of which 
40 mg of tissue is used as mentioned above. 
 Add the correct volume and additional RIPA buffer used to make equal volume (15 µl) as 
well as 15µl Laemlli’s sample buffer added in 1:1 ratio total volume should be 30 µl.  
 Once added Eppendorf tubes were punctuated with needle  
  Proteins are denatured by boiling for 5 minutes at 95oC.  
 Samples Centrifuged at 10 000 rpm quickly  
 Use immediately for gel electrophoresis or freezer at -80ºC. 
8.4 Assembly of Gel for electrophoresis 
 Clean glass plates and rubber with 70% alcohol 
Stellenbosch University  https://scholar.sun.ac.za
  
116 
 
 
 Place frames into the caskets and align glass frames clip into place( make sure the 
smaller plate faces forward) 
 Make a 1.00 mm mini Gel (10 wells) using BIO-RAD TGX stain free ™ Fastcast ™ 
Gels add the required components to make the stacker and resolver according to table 
7.4. 
Table 7.4: Component to make 12% Stain free™ Fastcast™ Gel 
1.0mm Bio-Rad Glass plates(n=gels) 
 Stacker Resolver 
Resolver A - 3 ml x n 
Resolver B - 3 ml x n 
Stacker A 1 ml x n - 
Stacker B 1 ml x n - 
Total Volume 2 ml x n 6 ml x n 
TEMED 2 µl x n 3 µl x n 
10% APS 10 µl x n 30 µl x n 
 
 First add Resolver using a Pasteur pipette to the top of the green line  
 Add the stacker using a Pasteur pipette and gently place the comb to avoid air bubbles 
 Allow gel to set ( ± 1 hour) 
 Boiled samples for 5 minutes at 95oC 
 Centrifuge quickly 
 Remove gel from casket and place into Bio-rad chamber  
 Place gels facing towards buffer dam and clamp in, add Running buffer in middle 
compartment and the outside well 
 Carefully remove the comb from the gel 
8.5 Loading samples 
 Pipette using special loading tips 5 µl BLUeye Prestained ladder into the first well of 
the gel 
 Pipette samples in the rest of the wells see Figure 7.5 
 Add more running buffer to the outside compartment 
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 Place lid onto the tank and ensure the electrodes are oriented accordingly red with red 
and black with black. 
 Set machine to 100 V, and current of 300 mA for approximately 60-90 minutes 
8.6 Membrane transfer 
 Once gels have run they are transferred using transfer blot to nitrocellulose membrane.  
 Using Trans-Blot® Turbo™ RTA Mini PVDF Transfer Kit 
 Immerse nitocellulose membrane in 30 ml  1x transfer buffer for 3 minutes 
 Immerse PVDF in 100% methanol until translucent, then equilibrate membrane in 1x 
transfer buffer for 3 minutes 
 Immerse 2 stacks of transfer stacks in 50 ml transfer buffer for 3 minutes 
 Assemble as follows 
o Place one transfer stack at the bottom of cassette 
o Place wetted membrane on the stack 
o  Remove gel from glass casket and remove staking gel section, gently place gel 
on membrane ( remove air bubbles using  blot roller)  
o Place second wetted transfer stacker on top 
 Roll the assembled sandwich with blot roller  
 Remove excessive transfer buffer 
 Close and lock cassette lid, Insert cassette in to Trans-Blot® Turbo™ transfer system 
 Setting: 30 minutes at 25 V ,1.0 A 
 After transferred membrane were soak in 100% methanol and dried 
 Gels and wetted Membrane were checked using the ChemiDoc™ XRS+ System 
 Membrane washed in 1x TBS-T (5 minutes ,3x) 
 Blocked in blocking buffer (5% milk) for a 2 hour.  
 Membrane was placed in 1x TBS-T containing specific primary antibody probing for 
48 hours at 4 ºC. 
 Membrane was washed again in 1x TBS-T (3x for 5 minutes)  
 Placed in secondary antibody for 1 hour at room temperature.  
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Figure 7.5 Loading samples into gel for electrophoresis 
 
Table 7.5: Primary and secondary antibodies used for western blot analysis  
Primary 
Antibody 
Molecular weight 
(kDa) 
Secondary  
Antibody 
Dilution  
factor 
Company and Catalogue 
# 
Caspase-
3 
Total: 35 kDa 
Cleaved: 17 and 19 
kDa 
Anti-Rabbit 1:1000 
Cell Signalling Technology  
#9662S 
PARP1 
Total:116 kDa 
Cleaved: 89 kDa 
Anti-Rabbit 1:1000 
Cell Signalling Technology  
#9532S 
Secondary Antibody 
Anti-Rabbit Secondary HRP-Linked 1:10000 
Cell Signalling Technology  
#7074S 
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8.7 Image analysis  
 Using Chemi-Doc (Bio-Rad) image membrane by addition of ECL (1:1 ratio) reagent, 
200 µl should be sufficient for membrane if protein of interest molecular weight is 
known. 
  Run specific protocol set image frame at 9.1 x 7.5: 
 Membrane (band of interest):     
o Application Blot Chemi 
(With the addition of ECL) 
 Total protein:       
o ApplicationBlot Stain free 
 Image of Ladder:      
o Application Blot Colometric 
 And images and run protocol report will display. Save images.  
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Protocol 9: Histological preparation of tissue 
9.1: Tissue processing  
For histological analysis, the 10% neutral formalin-fixed heart tissue was placed in a pre-
labelled embedding cassette. The tissue was then processed using the Shandon Elliott Suplex 
processor (Biotech lab, SCE 0540, UK) using a 20-hour processing protocol outlined as 
follows:  
Table 7.6: 20-hour Automated Tissue processing procedure 
Step Solution Time (Hours) 
Dehydration 
70% alcohol 1.5 
70% alcohol 1.5 
90% alcohol 1.5 
95% alcohol 1.5 
95% alcohol 1.5 
100% alcohol 1.5 
100% alcohol 1.5 
100% alcohol 2 
Clearing 
Xylene 1.5 
Xylene 2 
Impregnation 
Paraplast® wax 2 
Paraplast® wax 2 
 
9.2: Embedding tissue  
 Processed tissue is placed into the appropriate mould size from cassette add a small 
amount of molten paraffin wax and place tissue in correct orientation for sectioning. 
 Cool so that tissue can remain in correct orientation and fill the rest of the mould with 
moulted paraffin wax followed by the labelled cassette to hold mould down. 
  Place on cold plate and allow wax to solidify (±30 minutes) 
  Once complete mould can be removed from moulding block.  
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9.3: Sectioning using microtome 
 Before actual section/ ribbons of tissue can be made the blocks require trimming to get 
to the tissue.  
 Place tissue in freezer for 30 minutes. 
  Set up water bath as well as glass slides to collect tissue.  
 Trim until ribbon of tissue form.  
 Pick up ribbon of tissue with glass slide at 90o angle. 
  Place 2 times ribbon of each tissue on to different slides  
 Place slides in oven (70oC). 
 Once wax has melted, slides are ready for staining.  
Protocol 10: H and E staining  
10.1 Staining procedure (using automated system)  
 De-wax and hydrate paraffin sections.  
 Cleared in xylol 
 Dehydrate in three changes of 100% ethanol (100%, 95% and 70%). 
 Rinse in distilled water 
 Stain Harris hematoxylin 
 Rinse in distilled water  
 Add 10% acid alcohol 
 Scott’s tap water 
 Distilled water 
 Eosin 
 Distilled water  
 Dehydrate in three changes of ethanol (70%, 95% and 100%). 
  Clear in xylene and mount in resinous media.  
 
Stellenbosch University  https://scholar.sun.ac.za
  
122 
 
 
Protocol 11: Picro-sirius red solution staining for collagen  
11.1 Staining procedure 
 De-wax and hydrate paraffin sections.  
 Stain nuclei with haematoxylin for 8 minutes 
  Rinse the slides for 10 minutes in running water. 
  Stain in picro-siruis red for 1 hour. 
  Wash in acidified water (see Appendix C).  
 Vigorously shake water from slide. 
 Dehydrate in three changes of 100% ethanol. 
  Clear in xylene and mount in resinous media.  
 
Protocol 12: Quantification of fibrotic tissue  
 Protocol obtained online: [Quantifying Stained Liver Tissue 
https://imagej.nih.gov/ij/docs/examples/stained-sections/index.html 5/5 | Examples] 
 Using Image J software 
12.1 Change the scale to micrometres  
 Measure the length of the scale bar and using the Analyse >Set Scale command to set 
the scale to micrometres.  
 Measure the scale bar, use the straight line selection tool (fifth tool from the left on the 
Image J tool bar) to create a line selection along the length of the scale bar. 
 Open the Analyze>Set Scale dialog box. Notice that the length of the line selection (317 
pixels) is automatically entered as the "Distance in Pixels". Enter the scale bar length 
(200 µm) as the "Known Distance" and "um" as the "Unit of Length". Image J will 
automatically convert the "u" to the micrometre symbol (µ). Click "OK" and notice that 
the image size has changed to 858.95x646.74 µm.  
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12.2 Convert the image to grayscale  
 Use the Image>Type>RGB Stack command to split the image into red, green and blue 
channels. This is necessary because the Image>Adjust>Threshold tool only works with 
grayscale images.  
 Move the slider to view each of the channels. Notice that the green channel has the best 
separation.  
 Use the Image>Stacks>Make Montage command to view all three channels at the same 
time. 
  Select the RGB stack (with the Green channel selected) and press shift-t 
(Image>Adjust>Threshold). The "Threshold" tool opens and the green channel is 
automatically threshold. 
  Manually adjusted the threshold. Do this by moving the lower slider until the stained 
collagen is highlighted in red. Notice that the threshold level arrived at manually is about 
half the automatically set level of 175. 
  Click on "Set" and set the upper level to 175/2, or 87. Setting a threshold that is a 
fraction of the automatically determined threshold will allow us to later create a macro 
that does not require manual thresholding.  
12.3 Segment (isolate) the red-stained collagen using thresholding 
 Erase the scale bar to prevent it from being included in the calculated area. Select 
rectangular selection tool to select the scale bar, then press Backspace (Delete on the 
Mac).  
o If the current background is not white, use the color picker tool 
(Image>Color>Color Picker) to change it to white. Note that the current 
background color is indicated by the color of the border surrounding the eye 
dropper tool icon. 
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12.4 Measure the threshold area  
 Command Image J what to measure by opening the Analyze>Set Measurements dialog 
and checking "Area", "Area Fraction", "Limit to Threshold" and "Display Label".  
 Press "m" (Analyse>Measure) and the area and percent area will be displayed in the 
"Results" window.  
 Right click in the "Results" window and select "Save As" to save the results as a tab-
delimited text file or select "Copy" to copy the results to the Clipboard transfer results 
to Excel Spreadsheet.  
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7.3 Appendix C-Reagents and solutions preparation 
Protocol 1: Growth Media (500ml) 
1.1 Materials: 
 500 ml Dulbecco’s Modified Eagle Medium (DMEM) 
 50 ml 10% Fetal Bovin Serum (FBS) 
 5 ml Penicillin Streptomycin (PenStrep) 
 
1.2 Preparation: 
 Work at a temperature of 37 ºC 
 Place 500 ml DMEM in shaking incubator to bring temperature to 37 ºC remove 55 ml 
DMEM from stock bottle 
 Add 50 ml filtered 10% FBS and 5 ml PenStrep and swirl mixture. 
 Make aliquots of 50 ml in falcon tubes , cover with parafilm and store at 4 ºC 
Protocol 2: Doxorubicin stock 
 Under sterile conditions , make a stock of DOX  
 Weigh out 0.002 g DOX and dissolve in 400 ml HBSS 
 5 mg/ml or 5 µg/µl STOCK 
 Vortex, make aliquots in Eppendorf tubes 
 Wrap in foil Store at -20 ºC 
Protocol 3: Phosphate buffer 50 mM, pH 7.5 (100 ml)  
 Dissolve 0.7098 g Na2HPO4 in 100 ml dH2O and mix- solution 1 
 Dissolve 0.029 g of EDTA in 100 ml dH2O and mix- solution 2 
 Add 18 ml of solution 1 with 82 ml of solution 2, adjust pH to 7.4  
 Store at 4ºC  
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Protocol 4: Thirobuturic Acid (0.11M) 
 Concentration of 0.11M in 0.11M NaOH 
 𝑁(𝑚𝑜𝑙) =
𝑚(𝑔𝑟𝑎𝑚𝑠)
𝑀𝑟(𝑔𝑟𝑎𝑚𝑠 𝑚𝑜𝑙)⁄
 
 Therefore m (grams)= Mr(grams/mol) x N(mol)   Equation 1 
**n =  
m
MR
 ……. m = MR x n  𝐶 =  
𝑛
𝑉
 …….. 𝑛 = 𝐶𝑉   
 therefore m(g) =  
 g = MR x C x V 
 = 144.15(mol/g) x 0.11M x 0.010L 
 = 0.159g TBA in 10 mL of NaOH 
 Add 0.159g TBA in 10 ml NaOH 
 Protocol 5: 10% Neutral Formalin Buffer (1 Litre) 
 100 ml 37% Formaldehyde  
 4 g Sodium phosphate monobasic 
 7.5 g Sodium phosphate dibasic (Na2HPO4) 
 pH to 6.8 and top up with dH2O to make 1 Liter 
Protocol 6: Different ethanol preparations (1 Litre) 
100%  use pure ethanol  
95%  dilute 950 ml of 100% ethanol in 50 ml dH2O 
90%   dilute 900 ml of 100% ethanol in 100 ml dH2O 
70%   dilute 700 ml of 100% ethanol in 300 ml dH2O 
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Protocol 7: Radio immunoprecipitation (RIPA) assay buffer (STOCK) 
 50 mM Tris-HCL 
o Add 700 mg Tris to 75ml dH2O 
 Add 900 mg NaCl and stir the adjust pH to 7.4 
 Add 10% NP-40 
o Dissolve 1 ml NP-40 in 9ml dH20 
 Add 2.5 ml Sodium –deoxycholate 
o  Dissolve 1g in 10ml 
 Add 1 ml EDTA(1 mM) 
o 44.67 mg in 1.2 ml dH2O 
 Aliquot and store 4ºC 
Protocol 8: RIPA assay buffer (working solution) 1ml  
For 1 ml RIPA (STOCK) add: 
 42 µl Protease inhibitor cocktail(PI) [-20ºC] 
 5 µl  Sodium Fluoride (NaF) [room temperature] 
 5 µl Sodium orthovanadate (Na2VO4) [-20ºC] 
 10 µl Pheylmethylsulponyl Fluoride (PMSF) [ 4ºC] 
Preparation is kept on ice 
Protocol 9: Laemmli’s Sample buffer (STOCK) 
 16 ml dH2O 
 5 ml 0.5 M Tris- HCL , pH 6.8 
 4 ml glycerol 
 8 ml 10% (w/v) Sodium dodecyl sulphate (SDS) 
o Dissolve 1 g in 10 ml 
 2 ml 0.05% ( w/v) Bromophenol blue  
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STORE at room temperature covered with foil 
Protocol 10: Laemmli’s Sample buffer (Working STOCK) 
 850 µl Laemmli’s Sample buffer (STOCK) 
 150 µl β-meracpatonol 
Add together on the day of usage  
Protocol 11: Running Buffer (1 litre)  
 100 ml Tris- glycine- SDS buffer (TGS) 10X [ready-made, BIO RAD] 
 900 ml dH2O 
 Storage 4ºC  
Protocol 12: Transfer Buffer-BIORAD kit (1Litre) 
 200 ml 5x transfer buffer [part of kit] 
 600 ml dH2O 
 200 ml ethanol 
 Mix reagents together keep at room temperature  
Protocol 13: 10x TBS (1 Litre) 
 24.5 g Tris 
 80 g NaCl 
 Dissolve in 600 ml distilled water, set pH to 7.6 and top up to 1 L with dH2O 
Protocol 14: 1x TBS-T (1Litre) 
 100 ml 10X TBS-T 
 900 ml dH2O 
 1 ml Tween 20 
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Protocol 15: Blocking Buffer (100 ml) 
 95 ml 1 X TBS-T  
 Add 5 ml Milk 
 Mix well on magnetic stirrer 
Protocol 16: 10% Ammonium persulphate 
 Weight out 0.1 g APS into Eppendorf tube and add 1 ml dH2O 
Protocol 17: Primary Antibody 
 Add 5 ml 1x TBS-T into falcon tube  
 Pipette 5 µl primary antibody into solution 
 Keep on ice  
Protocol 18: Secondary Antibody 
 Add 5 ml 1x TBS-T into falcon tube  
 Pipette 0.5 µl primary antibody into solution 
 Keep on ice  
Protocol 19: Paul’s Stripping Buffer 
Dissolve in 400ml dH2O: 
 7.5 g glycine 
 0.5 g SDS 
 Add 5 ml Tween 
 Adjust pH to 2.2 
 Top up to 500 ml 
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Protocol 20: 10% acid alcohol-acidified water (1 litre) 
 10 ml 1% HCl 
 Dissolved in 100% ethanol 
Protocol 21: Scott tap water (1 Litre) 
 3.5 g NaHCO3 
 20 g MgSO4 
 1 ml 37% formalin 
 1 litre dH2O 
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7.4 Appendix D: Equipment and Reagents list 
Table 7.7: Equipment used in experiments  
EQUIPMENT CATOLOGUE 
NUMBER 
COMPANY CITY  COUNTRY 
Accu-Chek ® Performa 
Nano 
 Roche  
Diagnostics  
Mannheim Germany 
Accutrend Plus®  Roche  
Diagnostics 
Mannheim Germany 
Bio-Plex® MAGPIX™ 
Multiplex reader 
MAGPIX13046704 Bio-Rad 
Laboratories, 
Inc. 
California USA 
ChemiDoc™  XRS+ 
System 
170-8265 Bio-Rad 
Laboratories, 
Inc. 
California USA 
Direct Detect™ 
Infrared Spectrometer 
DDHW00010 Merck Massachusetts USA 
Leica AutoStainer XL ST5010 Leica 
Biosystems 
Wetzlar Germany 
Leica microtome RM 2125 RT Leica 
Biosystems 
Wetzlar Germany 
Leica Modular Tissue 
Embedder 
EG1160 Leica 
Biosystems 
Wetzlar Germany 
Mini - PROTEAN® II 
electrophoresis cell 
165-2940 Bio-Rad 
Laboratories, 
Inc. 
California USA 
Thermo Scientific 
Multiskan®   Spectrum 
microplate and 
Spectrophotometer 
51119200 Thermo Electron 
Corporation 
Massachusetts USA 
Multiskan® Spectrum 
plate reader 
51118600 Thermo Fisher 
Scientific 
Massachusetts USA 
Nikon Eclipse E400 
microscope 
 Nikon 
Instruments 
Tokyo Japan 
POLYTRON® PT2100 
Homogenizer 
 Thermo Fisher 
Scientific 
Massachusetts USA 
SPOT RT Color Digital 
Camera  
( Microscope) 
 Diagnostics 
Instruments, Inc. 
 USA 
Shandon Elliot Suplex 
processor 
SCE 0540 Biotech 
laboratories  
 UK 
Trans-Blot® Turbo™ 
transfer system 
1704270 Bio-Rad 
Laboratories, 
Inc. 
California USA 
Ultrasonic Liquid 
processor 
630-0427 Sonics & 
Material, Inc. 
Newtown USA 
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Table 7.8: Reagents and material used to perform experiments  
REAGENT/MATE
RIAL 
ABBREVIATIONS CATOLOGUE 
NUMBER 
COMPANY CITY 
COUNTRY 
1% Nondet P 40 NP40 74385-1L Sigma-
Aldrich 
Missouri 
USA 
2-Mercaptoethanol  M6250 Sigma-
Aldrich 
Missouri 
USA 
Na-deoxycholate Na D6750 Sigma-
Aldrich 
Missouri 
USA 
Acetic acid (glacial)  537020 Sigma-
Aldrich 
Missouri 
USA 
Ammonium 
Persulphate 
APS A3678-25G Sigma-
Aldrich 
Missouri 
USA 
BluEye Prestained 
ladder  
Protein Ladder PM007-0500 Biocom 
Biotech 
Centurion 
South Africa 
Bromophenol blue  SAAR1437500CB Merck  Massachuset
ts  
USA 
Butylated 
hydroxytroluene 
BHT B1378 Sigma-
Aldrich 
Missouri 
USA 
Chloroform  102444 Merck 
Millipore 
Massachuset
ts  
USA 
Clarity™ ECL 
Western Blotting 
Substrate 
 1705061 Bio-Rad 
Laboratories, 
Inc. 
California 
USA 
Container 
specimen jar 40ml 
 PTLC1468R1 
 
Lasec Cape Twon 
South Africa  
Cyclohexane  102822 Merck  Massachuset
ts  
USA 
Doxorubicin 
Hydrochloride 
DOX D5794 LKT 
®laboratories 
Minnesota 
USA 
DPX mounting 
medium 
 06522 Sigma-
Aldrich 
Missouri 
USA 
Dulbecco’s 
Modified Eagle 
Medium 
DMEM 41965-062 LifeTechnolo
gies 
California  
USA 
DTNB  D21820 Sigma-
Aldrich 
Missouri 
USA 
Ethylenediaminetet
raacetic acid 
EDTA EDS-100G Sigma -
Aldrich 
St Louis 
USA 
Embedding  
cassettes 
 Z672122 Sigma- 
Alrich 
Missouri 
USA 
Ethanol 99.9%   32221 Reidel 
deHaen 
Seelze 
Germany 
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REAGENT 
/MATERIAL 
ABBREVIATIONS CATOLOGUE 
NUMBER 
COMPANY CITY 
COUNTRY 
Eosin solution E 3801600E Leica 
Biosystems 
Wetzlar 
Germany 
Fetal Bovin Serum  FBS FBS-G1-12A Biocom 
Biotech 
Centurion 
South Africa  
Formaldehyde  
sol min. 37% 
 K46046503441 Merck Massachuset
ts  
USA 
Glycine  357002-1KG Mecrk Massachuset
ts  
USA 
Glycerol  SAAR2676520 Merck Massachuset
ts  
USA 
Hank’s balanced 
salt 
soloution(modified)  
HBSS H8264  Sigma-
Aldrich 
Missouri 
USA 
Hydrochloric acid HCL SAAR3063040LP Merck Massachuset
ts  
USA 
Isoflurane   Isofor Safeline 
Pharmaceuti
cal 
Florida South 
Africa  
Mayer’s 
haematoxylin 
solution 
H SAAR2822001LC Merck  Massachuset
ts 
USA 
Minicollect ® 
K3EDTA Blood 
collection tubes 
 VGRV450474R Lasec Cape Town 
South Africa 
Malondialdehyde MDA 820756 
805797 
Merck Massachuset
ts  
USA 
Methanol MeOH 1.06007 
UN1250 
 
Merck Massachuset
ts 
USA 
Microscope 
coverslips 
 GLAS2C9M2250
REC 
Lasec Cape Town 
 South Africa 
Microscope slides  GLAS4S22M300
F 
Lasec Cape Town 
 South Africa 
Milk  Everfresh Fat 
Free long life 
Spar Stellenbosch 
South Africa 
Ortho-phosphoric 
acid 
OPA 100573 
UN1805 
Merck Masschusett
s 
USA 
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REAGENT/ 
MATERIAL 
ABBREVIATIONS CATOLOGUE 
NUMBER 
COMPANY CITY 
COUNTRY 
Paraplast® wax  A6330-4LB Sigma- 
Aldrich 
Missouri 
USA 
Penicillin 
Streptomycin 
PenStrep 15140-122 LifeTechnolo
gies 
California  
USA 
Pheylmethylsulpon
yl Fluoride 
PMSF 93482-50ml-F Sigma-
Aldrich 
Missouri 
USA 
Picric acid  P6744-1GA Sigma-
Aldrich 
Missouri 
USA 
ProcartaPlex Mix & 
Match Mouse 4-
plex Luminex kit 
 PPX-04-
MXCE327 
Biocom-
Invitrogen 
Massachuset
ts 
USA 
cOmplete™ 
Protease inhibitor 
cocktail 
PI 11873580001 Roche Basel 
Switzerland 
Running Buffer  
Tris- glycine- SDS 
buffer(TGS) 10X 
 161-0772 Bio-Rad 
Laboratories, 
Inc. 
California 
USA 
Sirius Red 
 
Direct Red 80 365548 Sigma –Alrich  Missouri 
USA 
Sodium Cholride NaCl 1.06404 Merck Massachuset
ts  
USA 
Sodium dodecyl 
sulfate 
SDS L3771 
 
Sigma-
Aldrich 
Missouri 
USA 
Sodium fluoride NaF 193270 Merck  Masschusett
s 
USA 
Sodium hydroxide NaOH S5881 Sigma-
Aldrich 
Missouri 
USA 
Sodium phosphate 
monobasic 
NaH2PO4 S8282 Sigma-
Aldrich 
Missouri 
USA 
Sodium phosphate 
diabasic 
Na2HPO4 S3264 Sigma-
Aldrich 
Missouri 
USA 
Sodium 
orthovanadate 
 
Na3VO4 S6508 
 
Sigma-
Aldrich 
Missouri 
USA 
Syringe 1ml with 
29G Needle 
  Stelmed cc Stellenbosch 
South Africa 
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REAGENT/ 
MATERIAL 
ABBREVIATIONS CATOLOGUE 
NUMBER 
COMPANY CITY 
COUNTRY 
Tetramethylethylen
ediamine 
TEMED 1.10732.0100 Merck Masschusett
s 
USA 
Thiobarbituric Acid  TBA 
 
T5500 Sigma- 
Alrich 
Missouri 
USA 
TGX Stain-Free™ 
Fast Cast™ 
Acrylamide Kit, 
12% 
 1610185 Bio-Rad 
Laboratories, 
Inc. 
California 
USA 
Tris Basic  648310 Merck Masschusett
s 
USA 
Tran-Blot® 
Turbo™ RTA Mini 
PVDF Transfer Kit 
 1704272 Bio-Rad 
Laboratories, 
Inc. 
California 
USA 
Tween ®20   P1379 Sigma- 
Aldrich 
Missouri 
USA 
Trypsin-EDTA  25200072 LifeTechnolo
gies 
California  
USA 
Paraplast® wax  A6330-4LB Sigma- 
Aldrich 
Missouri 
USA 
Phenylmethylsulfo
nyl fluoride 
PMSF 93482 Sigma-
Aldrich 
Missouri 
USA 
Picric acid  P6744-1GA Sigma-
Aldrich 
Missouri 
USA 
cOmplete™ 
Protease inhibitor  
PI 11873580001 Sigma- 
Aldrich 
Missouri 
USA 
Running Buffer  
Tris- glycine- SDS 
buffer(TGS) 10X 
 
 161-0772 Bio-Rad 
Laboratories, 
Inc. 
California 
USA 
Xylene  1330-20-7 Sigma-
Aldrich 
Missouri 
USA 
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7.5 Appendix E: Grime scale  
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7.6 Appendix F: Ethics Letter
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